Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 1 of 82 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal 
Conjugate Vaccine Administered in Healthy Children 2 to 9 Years of Age  
Phase III, modified double -blind, randomized, parallel -group, active -controlled, multi -center trial to evalua te the 
immunogenicity and describe the safety of MenACYW conjugate vaccine compared to a licensed quadrivalent 
meningococcal conjugate vaccine in healthy children 2 to 9 years of age in the United States  and Puerto Rico 
Clinical Trial Protocol, Amendment 2 
Health Authority File Number(s):  BB-IND #:  14171 
WHO Universal Trial Number 
(UTN): U1111- 1161 -2625 
Trial Code:  MET35 
Development Phase:  Phase  III 
Sponsor:  Sanofi Pasteur Inc.  
Discovery Drive, Swiftwater, PA 18370 -0187, USA 
Investigational Product:  MenACYW conjugate vaccine: Meningococcal Polysaccharide (Serogroups 
A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine  
Form / Route: Liquid solution / Intramuscular (IM)  
Indication For This Study:  MenACYW conjugate vaccine as a single dose f or children 2 to 9 year s 
Manufacturer:  Same as Sponsor  
Coordinating Investigator  ,  
 
Sponsor’s Responsible Medical Officer:  
 Sanofi Pasteur Inc.  
   
 
Product Safety Officer :  
 Sanofi Pasteur Inc. 
   
 
Clinical Trial Manager:   
 Sanofi Pasteur Inc. 
   
Version and Date of the Protocol:
 Version 3 .0 dated 23 February  2018 
This protocol version 3.0 is the second  amendment to the initial trial protocol version 1.0, dated 11 July 2016.  
Information contained in this publication is the propert y of Sanofi Pasteur  and is confidential. This information may not be 
disclosed to third parties without written authorization from Sanofi Pasteur . This document may not be reproduced, stored in a 
retrieval system, or transmitted in any form or by any means –electronic, mechanical recording, or otherwise –without prior 
authorization from Sanofi Pasteur . This document must be returned to Sanofi Pasteur  upon request.  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 1 of 83
Study ID: [REMOVED]

Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 2 of 82 History of Protocol Versions  
Table 1: Previous versions of the protoco l 
Version*  Date Comments  
1.0 11 July 2016 Original protocol; first version used in the study  
2.0 23 August 2017 Amendment 1  
*Versions in bold font have been approved by the Independent Ethics Committees (IECs)/ Institutional 
Review Boards (IRBs) and used in the study.  
 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 2 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 3 of 82 Table of Contents  
History of Protocol Versions ........................................................................................................... 2 
List of Tables  .................................................................................................................................... 8  
Synopsis ............................................................................................................................................ 9  
Table of Study Procedures  ............................................................................................................ 18  
List of Abbreviations  ..................................................................................................................... 20  
1 Introduction ..................................................................................................................... 22  
1.1 Background ..................................................................................................................... 22  
1.2 Background of the Investigational Product ..................................................................... 23  
1.2.1  Non-clinical Safety  ....................................................................................................... 23  
1.2.2  Clinical  ......................................................................................................................... 23  
1.2.2.1  Study MET39 (Phase II) ............................................................................................ 24  
1.2.2.2  Study MET44 (Phase II) ............................................................................................ 25  
1.2.2.3  Study MET50 (Phase II) ............................................................................................ 25  
1.2.2.4  Study MET54 (Phase II) ............................................................................................ 26  
1.3 Potential Benefits and Risks ........................................................................................... 27  
1.3.1  Potential Benefits to Subjects  ....................................................................................... 27  
1.3.2  Potential Risks to Subjects ........................................................................................... 28  
1.4 Rationale for the Trial  ..................................................................................................... 29  
2 Trial Objectives  ............................................................................................................... 29  
2.1 Primary Objective  ........................................................................................................... 29  
2.2 Secondary Objectives  ...................................................................................................... 30  
2.3 Obser vational Objectives  ................................................................................................ 30  
3 Investigators and Trial Organization ............................................................................ 30  
4 Independent Ethics Committee / Institutional Review Board  .................................... 31  
5 Investigational Plan  ......................................................................................................... 31  
5.1 Description of the Overall Trial Design and Plan ........................................................... 31  
5.1.1  Trial Design  .................................................................................................................. 31  
5.1.2  Justification of the Trial Design  ................................................................................... 32  
5.1.3  Trial Plan  ...................................................................................................................... 32  
5.1.4  Visit Procedures  ............................................................................................................ 34  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 3 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 4 of 82 5.1.5  Planned Trial Calendar ................................................................................................. 36  
5.1.6  Early Safety Data Review ............................................................................................. 36 
5.2 Enrollment and Retention of Trial Population ................................................................ 37  
5.2.1  Recruitment Procedures  ................................................................................................ 37  
5.2.2  Informed Consent Procedures ...................................................................................... 37  
5.2.3  Screening Criteria  ......................................................................................................... 38  
5.2.4  Inclusion Criteria  .......................................................................................................... 38  
5.2.5  Exclusion Criteria  ......................................................................................................... 38  
5.2.6  Medical History  ............................................................................................................ 40  
5.2.7  Contraindications  for Subsequent Vaccinations ........................................................... 40  
5.2.8  Contraindications for Subsequent Blood Samples ....................................................... 40  
5.2.9  Conditions for Withdrawal ........................................................................................... 40  
5.2.10  Lost to Follow-up Procedures....................................................................................... 41  
5.2.11  Classification of Subjects Who Discontinue the Trial .................................................. 41  
5.2.12  Follow-up of Discontinuations ..................................................................................... 42  
5.2.13  Follow-up and Reporting of Pregnancies ..................................................................... 42  
5.3 Safety Emergency Call  ................................................................................................... 42  
5.4 Modification of the Trial and Protocol ........................................................................... 43  
5.5 Interruption of the Trial .................................................................................................. 43  
6 Vaccines Administered  ................................................................................................... 43  
6.1 Identity of the Investigational Product ............................................................................ 43  
6.1.1  Identity of Trial Product  ............................................................................................... 43  
6.1.1.1  Composition  ............................................................................................................... 44  
6.1.1.2  Preparation and Administration  ................................................................................. 44  
6.1.1.3  Dose Selection and Timing ........................................................................................ 44  
6.1.2  Identity of Control Product ........................................................................................... 44  
6.1.2.1  Composition  ............................................................................................................... 45  
6.1.2.2  Preparation and Administration  ................................................................................. 45  
6.1.2.3  Dose Selection and Timing ........................................................................................ 45  
6.2 Identity of Other Products ............................................................................................... 45  
6.3 Product Logistics ............................................................................................................ 45  
6.3.1  Labeling and Packaging ............................................................................................... 45  
6.3.2  Product Shipment, Storage, and Accountability ........................................................... 46  
6.3.2.1  Product Shipment ....................................................................................................... 46  
6.3.2.2  Product Storage .......................................................................................................... 46  
6.3.2.3  Product Accountability ............................................................................................... 46  
6.3.3  Replacement Doses ....................................................................................................... 47 
6.3.4  Disposal of Unused Products ........................................................................................ 47  
6.3.5  Recall of Products ......................................................................................................... 47  
6.4 Blinding and Code-breaking Procedures ........................................................................ 47  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 4 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 5 of 82 6.5 Randomization and Allocation Procedures ..................................................................... 48  
6.6 Treatment Compliance  .................................................................................................... 48  
6.7 Concomitant Medications and Other Therapies  ............................................................. 48  
7 Management of Samples ................................................................................................. 49  
7.1 Sample Collection  ........................................................................................................... 50  
7.2 Sample Preparation  ......................................................................................................... 50  
7.3 Sample Storage and Shipment ........................................................................................ 50  
7.4 Future Use of Stored Serum Samples for Research  ........................................................ 51  
8 Clinical Supplies  .............................................................................................................. 51  
9 Endpoints and Assessment Methods  ............................................................................. 52  
9.1 Primary Endpoints and Assessment Methods ................................................................. 52  
9.1.1  Immunogenicity ............................................................................................................ 52  
9.1.1.1  Immunogenicity Endpoint .......................................................................................... 52  
9.1.1.2  Immunogenicity Assessment Method ........................................................................ 52  
9.1.2  Safety  ............................................................................................................................ 52  
9.1.3  Efficacy  ......................................................................................................................... 52  
9.2 Secondary Endpoints and Assessment Methods ............................................................. 53  
9.2.1  Immunogenicity ............................................................................................................ 53  
9.2.1.1  Immunogenicity Endpoints ........................................................................................ 53  
9.2.1.2  Immunogenicity Assessment Method ........................................................................ 53  
9.2.2  Safety  ............................................................................................................................ 53  
9.2.3  Efficacy  ......................................................................................................................... 53  
9.3 Observational Endpoints and Assessment Methods ....................................................... 53  
9.3.1  Immunogenicity ............................................................................................................ 53  
9.3.1.1  Immunogenicity Endpoints ........................................................................................ 53  
9.3.1.2  Immunogenicity Assessment Methods ...................................................................... 54  
9.3.2  Safety  ............................................................................................................................ 54  
9.3.2.1  Safety Definitions  ....................................................................................................... 54  
9.3.2.2  Safety Endpoints ........................................................................................................ 57  
9.3.2.3  Safety Assessment Methods ....................................................................................... 57  
9.3.2.3.1  Immediate Post -vaccination Surveillance Period .................................................... 58  
9.3.2.3.2  Reactogenicity (Solicited Reactions From Day  0 to Day 07 After 
Vaccination)  ............................................................................................................. 58  
9.3.2.3.3  Unsolicited Non- serious Adverse Events From Day  0 to Day 30 After 
Vaccination  .............................................................................................................. 62  
9.3.2.3.4  Serious Adverse Events  ........................................................................................... 63  
  ..........................................................................  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 5 of 83

Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 6 of 82 9.3.2.3.6  Medically -Attended Adverse Events  ....................................................................... 64  
9.3.2.3.7  Assessment of Causality  .......................................................................................... 64  
9.3.3  Efficacy ......................................................................................................................... 64  
10 Reporting of Serious Adverse Events ............................................................................ 64  
10.1  Initial Reporting by the Investigator  ............................................................................... 65  
10.2  Follow-up Reporting by the Investigator ........................................................................ 65  
10.3  Reporting of SAEs Occurring After a Subject Has Completed the Study ...................... 66  
10.4  Assessment of Causality  ................................................................................................. 66  
10.5  Reporting SAEs to Health Authorities and IECs / IRBs ................................................. 66  
11 Data Collection and Management ................................................................................. 67  
11.1  Data Collection and CRF Completion ............................................................................ 67  
11.2  Data Management  ........................................................................................................... 68  
11.3  Data Review  .................................................................................................................... 68  
12 Statistical Methods and Determination of Sample Size  ............................................... 69  
12.1  Statistical Methods .......................................................................................................... 69  
12.1.1  Hypotheses and Statistical Methods for Primary Objective  ......................................... 69  
12.1.2  Hypotheses and Statistical Methods for Secondary Objectives ................................... 69  
12.1.2.1  Secondary Objective 1  ............................................................................................... 69  
12.1.2.2  Secondary Objective 2  ............................................................................................... 70  
12.1.2.3  Secondary Objective 3  ............................................................................................... 70  
12.1.3  Statistical Methods for Observational Objectives  ........................................................ 70  
12.1.3.1  Immunogenicity ......................................................................................................... 70  
12.1.3.2  Safety  .......................................................................................................................... 71  
12.2  Analysis Sets ................................................................................................................... 72  
12.2.1  Full Analysis Set ........................................................................................................... 72  
12.2.2  Safety Analysis Set  ....................................................................................................... 72  
12.2.3  Per-Protocol Analysis Set ............................................................................................. 72  
12.2.4  Populations Used in Analyses ...................................................................................... 73  
12.3  Handling of Missing Data and Outliers .......................................................................... 73  
12.3.1  Safety  ............................................................................................................................ 73  
12.3.2  Immunogenicity ............................................................................................................ 73  
12.3.3  Efficacy  ......................................................................................................................... 73  
12.4  Interim / Preliminary Analysis ........................................................................................ 74  
12.5  Determination of Sample Size and Power Calculation  ................................................... 74  
13 Ethical and Legal Issues and Investigator / Spons or Responsibilities ........................ 74  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 6 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 7 of 82 13.1  Ethical Conduct of the Trial / Good Clinical Practice  .................................................... 74  
13.2  Source Data and Source Documents ............................................................................... 75  
13.3  Confidentiality of Data and Access to Subject Records ................................................. 75  
13.4  Monitoring, Auditing, and Archiving ............................................................................. 75  
13.4.1  Monitoring .................................................................................................................... 75  
13.4.2  Audits and Inspections ................................................................................................. 76  
13.4.3  Archiving ...................................................................................................................... 76  
13.5  Financial Contract and Insurance Coverage ................................................................... 77  
13.6  Stipends for Participation  ................................................................................................ 77  
13.7  Publication Policy  ........................................................................................................... 77  
14 References List  ................................................................................................................. 78  
15 Signature Pages  ............................................................................................................... 82  
 
 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 7 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 8 of 82 List of Tables  
Table 1: Previous versions of the protocol ........................................................................................2  
Table 5.1: Testing strategy for N meningitidis  serogroups A, C, Y, and W ....................................33  
Table 9.1: Solicited injection site reactions: terminology, definitions, and intensity scales  ...........60  
Table  9.2: Solicited systemic reactions: termino logy, definitions, and intensity scales .................61  
Table 12.1: Power of the study based on the primary objective .....................................................74  
 
 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 8 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 9 of 82 Synopsis 
Company:  Sanofi Pasteur  
Investigational  Product:  MenACYW conjugate vaccine 
Active Substances:  Capsular polysaccharide from meningococcal serogroups A, C, Y, and W 
conjugated to tetanus toxoid  
  
Title of the Trial:  Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Con jugate Vaccine Administered in Healthy Children 2 to 
9 Years of Age  
Development Phase:  Phase III  
Coordinating Investigator:  
 
Trial Centers:  This will be a multi -center trial with approximately 40 sites in the United 
States  and Puerto Rico . 
Investigators and sites will be  listed in the “List of Investigators  and Centers 
Involved in the Trial” document.  
Planned Trial Period:  1Q 201 7 to 4Q 201 7 
Trial Design and Methodology: This will be a Phase III, modified dou ble-blind, randomized, parallel- group, 
active -controlled, multi- center trial to evaluate the immunogenicity and 
describe the safety of MenACYW conjugate vaccine compared to MENVEO
® in healthy children 2 to 9 years of age in the United States  and 
Puerto Ric o. 
Approximately 1000 healthy , meningococcal -vaccine naïve children aged 2 
to 9 years will be randomized in a 1:1 ratio to the following 2 groups: 
Group 1: MenACYW conjugate vaccine  
Group 2: MENVEO® 
Enrollment will be stratified by age: 250  children 2 to 5 years old and 
250 children 6 to 9 years old, respectively, will be enrolled in each group . 
All subjects will provide blood samples for immunogenicity assessment at baseline (pre- vaccination) and at 30 to 44 days  after vaccination. Solicited 
adverse event (AE) information will be collected for 7 days a fter vaccination; 
unsolicited AE information will be collected from Visit  1 (Day [D] 0) to 
Visit  2 (D30 [+14 days ]), and serious adverse event (SAE) information 
 will be collected 
throughout the study period from D 0 through D180 (+14 days) after 
vaccination. Medically -attended adverse event s (MAAE s) will be collected 
from Visit 1 through Visit 2 (as part of the collection of unsolicited AE 
information) and f rom Visit  2 through D180  (+14 days)  (as MAAEs).   
A preliminary analysis of safety and immunogenicity, without 
immunogenicity data generated using rSBA , is planned for all subjects 
enrolled in the study.  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 9 of 83

Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 10 of 82 Early Safety Data Review:  This trial will not inclu de an early review of safety data (i.e., no early safety 
review[s] of preliminary safety data occurring at pre -determined milestones 
defined in the protocol  with pause in enrollment) . However, it may be 
interrupted at any time if new data about the investigational product become 
available, and/or on advice of the Sponsor, the Independent Ethics 
Committees ( IECs ) / Institutional Review Boards ( IRBs ), or the governing 
regulatory authorities in the country where the trial is taking place.  
If the trial is prem aturely terminated or suspended, the Sponsor will promptly 
inform the Investigators, the IECs/IRBs, and the regulatory authorities of the 
reason for termination or suspension. If the trial is prematurely terminated for 
any reason, the Investigator wi ll promptly inform the subjects’  parent(s) / 
guardian and should assure appropriate therapy and follow -up. 
Primary Objective:  To demonstrate the non -inferiority of the vaccine seroresponse to 
meningococcal serogroups A, C, Y, and W following the administration of a 
single dose of MenACYW conjugate vaccine compared to that observed 
following the administration of a single dose of MENVEO® in children aged 
2 to 9 years . 
Primary Endpoint : Vaccine sero response against meningococcal s erogroups A, C, Y, and W 
measured  by serum bactericidal assays using human complement (hSBA) 
assessed at baseline (D0, before vaccination) and 30 days (+14 days) after 
vaccination.  
Secondary Objectives:  1) To compare  the hSBA antibody geometric mean titer s (GMT s) of 
meningococcal serogroups  A, C, Y, and W following the 
administration of MenACYW conjugate vaccine to those observed 
following the administration of MENVEO® in children 2 to 9 years  of 
age 
2) To evaluate the hSBA antibody GMTs of meningococcal serogroups 
A, C, Y, and W following the administration of MenACYW conjugate 
vaccine and those observed following the administration of 
MENVEO® in children 2 to 5 years of age , and in children 6 to 9 years 
of age, respectively  
3) To evaluate  the hSBA vaccine seroresponse to meningococcal 
serogroups A, C, Y, and W before and 30 days (+14  days) post-
vaccination in children 2 to 5 years of age, and in children 6 to 9 years 
of age, respectively  
Secondary Endpoints:  • GMTs  against meningococcal serogroups A, C, Y, and W measured by 
hSBA before and  30 days (+14 days) after vaccination  with 
MenACYW conjugate vaccine or MENVEO® 
• Vaccine seroresponse against meningococcal serogroups A, C, Y, and 
W measured by hSBA before and 30  days (+14  days) after vaccination 
with MenACYW conjugate vaccine or MENVEO® 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 10 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 11 of 82 Observat ional Objectives:  Immunogenicity  
1) To describe the antibody titers against meningococcal serogroups A, C, 
Y, and W measured by hSBA  before and 30 days (+14 days) after 
vaccination with MenACYW conjugate vaccine or MENVEO® 
2) To describe the antibody titers agai nst meningococcal serogroups A, C, 
Y, and W measured by rSBA before and 30 days (+14  days) after 
vaccination with MenACYW conjugate vaccine or MENVEO® in a 
subset of subjects  
Safety  
To describe the safety profile of MenACYW conjugate vaccine and that of 
the licensed MENVEO®  
Observational Endpoints:  Immunogenicity  
1) Antibody titers against meningococcal serogroups A, C, Y, and W 
measured by hSBA before and 30 days after vaccination with 
MenACYW conjugate vaccine or MENVEO® 
2) Antibody titers against meningococc al serogroups A, C, Y, and W 
measured by rSBA before and 30 days after vaccination with 
MenACYW conjugate vaccine or MENVEO® in a subset of subjects  
Safety  
• Occurrence, nature (Medical Dictionary  for Regulatory Activities 
[MedDRA] preferred term), duration,  intensity, and relationship to 
vaccination of any unsolicited systemic AEs reported in the 30  minutes 
after vaccination.  
 • Occurrence, time of onset, number of days of occurrence, intensity, 
action taken, and whether the reaction led to early termination from the 
study, of solicited (prelisted in the subject’s diary card and electronic 
case report form [CRF]) injection site reactions occurring up to 7  days 
after vaccination.  
• Occurrence, time of onset, number of days of occurrence, intensity, 
action taken, and whether the reaction led to early termination from the 
study, of solicited (prelisted in the subject’s diary card and CRF) 
systemic reactions occurring up to 7 days after vaccination.  
• Occurrence, nature (MedDRA preferred term), time of onset, duration,  
intensity, action taken, relationship to vaccination (for systemic AEs 
only), and whether the event led to early termination from the study, of 
unsolicited AEs up to Visit  2 after vaccination.  
• Occurrence, nature (MedDRA preferred term), time of onset, dur ation, 
seriousness criteria, relationship to vaccination, outcome, and whether the SAE led to early termination from the study, of SAEs  
 throughout the trial.  
 • Occurrence, nature (MedDRA preferred term), time of onset , duration, 
seriousne ss, relationship to vaccination, and outcome for MAAE s from 
Visit  2 to the 6 -month follow -up contact. MAAE s will be collected as 
unsolicited AEs up to Visit  2. 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 11 of 83

Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 12 of 82 Planned Sample Size:  A total of 1000 children 2 to 9 years old  are planned to be enrolled: 
• Grou p 1 (MenACYW conjugate vaccine) : planned= 500 
(evaluable=400)  
Group  1a: 250 children 2 to 5 years of age  (from the day of the 2nd 
birthday to the day before the 6th birthday)  
Group  1b: 250 children 6 to 9 years of age  (from the day of the 6th 
birthday to th e day before the 10th birthday)  
• Group 2 (MENVEO®): planned=5 00 (evaluable=400)  
Group  2a: 250 children 2 to 5 years of age  (from the day of the 2nd 
birthday to the day before the 6th birthday)  
Group  2b: 250 children 6 to 9 years of age  (from the day of the 6th 
birthday to the day before the 10th birthday)  
The planned number of subjects is based on a 20% dropout rate 
(400 evaluable subjects in each group) allowing 90% power to reject the 
primary hypothes es simultaneously assuming the independence between 
each of the endpoints.  
Schedule of Study Procedures: Vaccination  
All subjects will receive a single  dose of either MenACYW conjug ate 
vaccine or MENVEO® at Visit 1  (D0). 
Blood sampling  
All subjects will provide a pre -vaccination blood sample at D0 and a post -
vaccination sample at Visit  2 (30 to 44 days after the vaccination at Visit  1). 
Antibodies to meningococcal serogroups A, C, Y, and W antigens will be measured by hSBA for all subjects, and by rSBA for a subset of subjects.  
Table S1: Testing strategy for N meningitidis  serogroups A, C, Y, and 
W 
 ACYW serogroups 
tested by hSBA*  
(all subjects)  ACYW 
serogroups tested 
by rSBA†  
(subset) 
Group 1   
Group 1a (2 to 5 years old) 250 100 
Group 1b (6 to 9 years old) 250 100 
Group 2   
Group 2a (2 to 5 years old ) 250 100 
Group 2b (6 to 9 years old ) 250 100 
* hSBA: serum bactericidal assay using human complement  
† rSBA: serum bactericidal assay using baby rabbit complement  
Collection of safety data  
• All s ubjects will be observed for 30  minutes after vaccination and a ny 
unsolicited systemic AEs occurring during that time will be recorded 
as immediate unsolicited systemic AEs in the CRF.  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 12 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 13 of 82  • The subject’s parent / guardian will record information in a diary card 
about solicited reactions from D0 to D 07 after vaccination and 
unsolicited AEs from D0 to Visit  2. SAEs will be reported throughout 
the duration of the trial.  
• The subject’s parent / guardian will record information only about 
possible SAEs and MAAE s in a memory aid (MA) from Visit  2 until 
the 6 -month (+14 day s) telephone call.  
• In addition, the subject’s parent / guardian  will be asked to notify the 
site immediately about potential SAEs at any time during the trial.  
• Staff will contact subject’s parent / guardian by telephone on D0 8 
(+2 days) to identify the occurren ce of any SAE not yet reported, and 
to remind them to complete the diary card up to Visit 2 and to bring it 
back at Visit 2.  
• The completed diary card will be reviewed with the  subject’ s parent / 
guardian at Visit  2. 
 • Staff will contact subject’s parent / guardian by telephone at 6  months 
(+14 days) post- vaccination to review the MA and identi fy the 
occurrence of any MAAE s as well as SAEs that may not have been 
reported.  
Duration of Participation in the 
Trial: The duration of each subject’s participation i n the trial will be approximately 
180 to 194 days.  
There will be a safety follow -up telephone call at 6 months (+14  days) after 
vaccination.   
Investigational Product:  MenACYW conjugate vaccine: Meningococcal Polysaccharide (Serogroups  A, C, Y, and W) Teta nus Toxoid Conjugate Vaccine  (Sanofi 
Pasteur Inc., Swiftwater, PA, USA)  
 Form:  Liquid s olution  
 Composition:  Each 0.5  milliliters ( mL) dose of MenACYW conjugate vaccine  is 
formulated in sodium acetate buffered saline solution to contain the following ing redients:  
Meningococcal capsular polysaccharides:  
Serogroup A  .............................................................. 10 micrograms ( µg) 
Serogroup C  .....................................................................................  10 µg 
Serogroup Y  .....................................................................................  10 µg 
Serogroup W  ....................................................................................  10 µg 
Tetanus toxoid protein carrier  .......................................  approximately 65  µg 
 Route:  Intramuscular (IM)  
 Batch Number:  To be determined  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 13 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 14 of 82 Control Product:  MENVEO®: Meningococcal (Groups A, C, Y and W -135) Oligo saccharide 
Diphtheria CRM 197 Conjugate Vaccine ( Novartis V accines and Diagnostics 
S.r.l., Sovicille , Italy) 
 Form:  Lyophilized powder and liquid components are combined to produce a 
solution for intramuscular injection  
 Composition:  Each 0.5  mL dose of vaccine contain the following active ingredients:  
MenA oligosaccharide  ......................................................................  10 µg 
MenC oligosaccharide  ........................................................................  5 µg 
MenY oligosaccharide  ........................................................................  5 µg 
MenW- 135 oligosaccharide  ................................................................ 5 µg  
CRM 197 protein  ..................................................................  32.7 to 64.1  µg 
Other ingredients per 0.5 mL dose: residual formaldehyde ≤  0.30 µg 
 Route:  IM 
 Batch Number:  To be determined (control product will be supplied by the Sponsor)  
Inclusion Criteria  An individual must fulfill all of the following criteria in order to be elig ible 
for trial enrollment:  
1) Aged 2 to 9 years on the day of inclusion  
2) Assent form has been signed and dated by the subject (as required by local regulations ) and informed consent form (ICF) has been signed and 
dated by the parent(s) or guardian  
3) Subject and parent / guardian are able to attend all scheduled visits and 
to comply with all trial procedures  
Exclusion Criteria:  An individual fulfilling any of the following criteria is to be excluded from 
trial enrollment:  
 1) Subject is pregnant, or lactating, or of childbearing potential and not 
using an effective method of contraception or abstinence from at least 
4 weeks prior to vaccination until at l east 4 weeks after vaccination. To 
be considered of non- childbearing potential, a female must be pre -
menarche.  
2) Participation in the 4 weeks preceding the trial vaccination or planned 
participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure  
 3) Receipt of any vaccine in the 4 weeks (28 d ays) preceding the trial 
vaccination or planned receipt of any vaccine prior to Visit 2 except for 
influenza vaccination, which may be received at least 2 weeks before or after the study investigational vaccines. This exception includes monovalent , multivalent , live , and attenuated  influenza  vaccines  
4) Previous vaccination against meningococcal disease
 with either the trial 
vaccine or another vaccine (i.e., mono- or polyvalent, polysaccharide, or 
conjugate meningococcal vaccine containing serogroups A, C, Y, or W ; 
or meningococcal B serogroup  containing vaccine) 
5) Receipt of immune globulins, blood or blood -derived products in the 
past 3 months  
6) Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti -cance r 
chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for 
more than 2 consecutive weeks within the past 3 months)  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 14 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 15 of 82  7) History of meningococcal infection, confirmed either cl inically, 
serologically, or microbiologically  
 8) At high risk for meningococcal infection during the trial (specifically, 
but not limited to, subjects with persistent complement deficiency, with 
anatomic or functional asplenia, or subjects traveling to countries with 
high endemic or epidemic disease)  
9) Known systemic hypersensitivity to any of the vaccine components, or history of a life -threatening reaction to the vaccines used in the trial or 
to a vaccine containing any of the same substances  
10) Verbal report o f thrombocytopenia, contraindicating intramuscular 
vaccination in the Investigator’s opinion  
 11) Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination in the 
Investigator’s opinion  
12) Personal history of Guillain -Barre syndrome (GBS)  
13) Personal history of an Arthus -like reaction after vaccination with a 
tetanus toxoid -containing vaccine  
14) Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with tria l conduct or completion 
 15) Moderate or severe acute illness/infection (according to Investigator’s judgment) on the day of vaccination or febrile illness (temperature 
≥ 100.4°F). A prospective subject should not be included in the study  
until the condition has resolved or the febrile event has subsided  
16) Receipt of oral or injectable antibiotic therapy within 72 hours prior to 
the first blood draw  
17) Identified  as a natural or adopted child of the Investigator or employee 
with direct involvement in the proposed s tudy 
Statistical Methods:  All immunogenicity analyses will be performed on the Per -Protocol 
Analysis Set (PPAS). Additional immunogenicity analyses will be performed for exploratory purposes on the Full Analysis Set (FAS). All 
safety analyses will be perf ormed on the Safety Analysis Set (SafAS).  
Primary Objective  
Thirty days (D30 [+14 days]) after the administration of MenACYW 
conjugate vaccine or MENVEO
®, the percentages  of subjects who achieve 
an hSBA vaccine seroresponse* for meningococcal serogroups A,  C, Y, and 
W in Group  1 are non -inferior to the corresponding percentages in Group 2. 
Null hypothesis (H 0): p (G1) - p (G2) ≤ -10% 
Alternative hypothesis (H 1): p (G1) - p (G2) > -10% 
where p  (G1) and p  (G2) are the percentages of subjects who achieve an hSBA 
vaccine seroresponse  in Group 1 and Group 2, respectively. Each of the 
serogroups A, C, Y, and W will be tested separately. If the lower limit of the 2-sided 95% confidence interval (CI) of the difference between the 
2 proportions is >  -10%, the inferiori ty assumption will be rejected.  
 Secondary  Objective s 
1) Thirty days (D30 [+14 days]) after the administration of MenACYW 
conjugate vaccine or MENVEO®, the hSBA geometric mean titer ratio 
(GMTR) between Group 1 and Group 2 will be calculat ed and 95% CI 
will be provided.  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 15 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 16 of 82  2) Thirty days (D30 [+14 days]) after the administration of MenACYW 
conjugate vaccine or MENVEO®, the hSBA GMTR  between Group  1a 
and Group  2a, and between Group  1b and Group  2b will be calculated 
and 95% CI will be provided , respectively . 
3) Thirty days (D30 [+14 days]) after the administration of MenACYW 
conjugate vaccine or MENVEO®, the difference of hSBA vaccine 
seroresponse* rates between Group 1a and Group 2a, and between 
Group  1b, and Group  2b will  be calculated and 95% CI will be 
provided, respectively . 
 *hSBA v accine seroresponse for serogroups A, C, Y, and W is defined as : 
• For a subject with a pre- vaccination  titer <  1:8, the post -vaccination 
titer must be ≥  1:16 
• For a subject with a pre- vaccination titer ≥  1:8, the post -vaccination 
titer must be at least 4 -fold greater than the pre -vaccination titer   
 Observational Objectives  
Immunogenicity  
Descriptive statistics will be provided for the antibody titers against 
meningococcal serogroups contained in MenACYW conjugate vaccine and 
MENVEO®. In general , categorical variables will be summarized and 
presented by frequency counts, percentages, and CIs. The 95% CIs of  point 
estimates will be calculated using the normal approximation for quantitative data and the exact binomial distribution (Clopper -Pearson method) for 
percentages. For GMTs, 95% CIs of point estimates will be calculated using 
normal approximation assumi ng they are log- normally distributed.  
Reverse cumulative distribution curve (RCDC) figures will be provided for 
the antibody titers against meningococcal serogroups contained in 
MenACYW conjugate vaccine and MENVEO
® treatment groups . 
Descriptive analyses on A, C, Y, and W serogroups on D0 and D30 
(+14  days) using hSBA will include but not be limited to:  
• GMT and 95% CI  in Group 1 , Group 2, Group 1a, Group 1b, Group 
2a, and Group 2b  
• Titer distribution and RCDC  
• Percentage of subjects with titer ≥ 1:4 and ≥ 1:8 and 95% CI in 
Group  1, Group  2, Group  1a, Group  1b, Group 2a, and Group  2b 
• Percentage of subjects with titer ≥ 4 -fold rise from pre -vaccination to 
post-vaccination, and 95% CI  in Group  1, Group  2, Group  1a, 
Group  1b, Group 2a, and Group  2b 
• Percentage of subjects with hSBA vaccine seroresponse*  and 95% CI 
in Group  1, Group  2, Group  1a, Group 1b, Group 2a, and Group  2b 
* hSBA vaccine seroresponse for serogroups A, C, Y, and W is defined as: 
• For a subject with a pre -vaccination titer < 1:8, the post -vaccination 
titer must be ≥ 1:16.  
• For a subject with a pre- vaccination titer ≥ 1:8, the post -vaccination 
titer must be at least 4 -fold greater than the pre -vaccination titer.  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 16 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 17 of 82  Descriptive analyses on A, C, Y, and W serogroups on D0 and D30 
(+14  days) using rSBA will include but not be limited to: 
• GMT and 95% CI in a subset of 200 subjects in Group 1 and Group 2, 
and in a subset of 100 subjects in Group 1a, Group 1b, Group 2a, and 
Group 2b  
• Titer distribution and RCDCs  
• Percentage of subjects with titer ≥ 1:8 and ≥ 1:128 and 95% CI in a 
subset of 200 subjects in Group 1 and Group 2, and in a subset of 
100 subjects in Group 1a, Group 1b, Group 2a, and Group 2b 
Percentage of subjects with titer ≥ 4 -fold rise from pre -vaccination to post -
vaccination, and 95% CI in a subset of 200 subjects in Group  1 and Group  2, 
and in a subset of 100 subjects in Group 1a, Group 1b, Group  2a, and Group 
2b 
 • Percentage of subjects with rSBA vaccine seroresponse* and 95% CI in 
a subset of 200 subjects in Group 1 and Group 2, and in a subset of 100 subjects in Group 1a, Group 1b, Group 2a, and Group 2b 
* rSBA vaccine seroresponse is defined as a post -vaccination  titer ≥  1:32 for 
subjects with pre -vaccination rSBA titer < 1:8, or a post -vaccination titer 
≥ 4 times the pre -vaccination titer for subjects with pre -vaccination rSBA 
titer ≥  1:8. 
Safety  
Safety results will be described for subjects in Group  1 and Group 2 . The 
main parameters for the safety endpoints will be described by 95% CIs (based on the Clopper -Pearson method).  
 Calculation of Sample Size:  
 
 
 
 
   
 
 
 
  
   
   
     
     
     
     
     
 
 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 17 of 83

Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 18 of 82 Table of Study Procedures  
Phase III Trial, 2 Visits, 1 Vaccination, 2 Telephone Calls, 2 Blood Samples, 180 Days Duration per Subject  
Visit/Contact Visit 1 Telephone 
Call (TC) 1 
 Visit 2 TC2 
Trial timelines (days) D0 D08 D30 D180 
Time windows (days)  -- +2 days  +14 days +14 days  
Informed consent form/assent form (if applicable)  X    
Inclusion/exclusion criteria  X    
Collection of demographic data  X    
Urine pregnancy test (if applicable)  X    
Medical history  X    
Physical examination * X    
Review of temporary contraindications for blood 
sampling†   X  
Randomization/allocation of subject number  X    
Blood sampling (BL), 5 mL ‡ BL1  BL2  
Vaccination§ X    
Immediate surveillance (30 minutes ) X    
Diary card provided X    
Telephone call   X**  X†† 
Recording of solicited injection site & systemic reactions D0 to D 07    
Recording of unsolicited AEs  D0 to Visit  2  
Recording of MAAE s‡‡    After Visit  2 to TC2 
Reporting of SAE s  To be reported throughout the study period  
Diary card reviewed and collected    X  
Collection of reportable concomitant medications X  X  
Memory aid (MA) provided***   X  
Termination of active phase of trial    X  
Completion of 6 -month follow -up    X 
*Temperature needs to be measured  by axillary , oral, or rectal  route (axillary is the preferred route) and recorded in source 
documents. 
†Should a subject receive oral or injectable antibiotic therapy within 3 days prior to the second blood draw, the Investigator will 
postpone that blood draw until it has been 3  days since the subject last received oral or injectable antibiotic therapy. 
Postponement must still be within the timeframe for blood draw (30 to 44 days after vaccination at D0). If postponement would 
result in the sample collection falling outside of this timeframe, the blood sample should be collected without postponement,  and 
it should be documented appropriately that the sample was taken less than 3  days after stopping antibiotic treatment.  
‡Blood sample a t Visit  1 will be drawn before administration of vaccine  
§Subjects will receive a single dose of MenACYW conjugate vaccine or a single dose of MENVEO®. 
**This call is made 8 to 10 days after the vaccination at Visit 1. If D 08 (+2  days) falls on a weekend or holiday, the telephone call 
may be made on the following business day. During this telephone call, the staff will find out whether the subject experience d 
any SAE not yet report ed, and will remind the subject’s parent/ guardian to continue using the diary card up to Visit  2, to bring the 
diary card to the study center at Visit 2, and confirm the date and time of Visit  2. 
††Staff will contact the subject’s parent/ guardian by telephone at 6 months (180 days +14  days) after vac cination at Visit  1 to 
identify the occurrence of any MAAE s as well as SAEs not yet reported.  
‡‡MAAE s that occur between Visit  1 and Visit  2 will be recorded as unsolicited AEs.  
§§  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 18 of 83

Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 19 of 82 ***The MA is used for the recording of SAEs  and MAAE s. The site staff will make a telephone call t o the parent/ guardian to 
obtain the information 180 days (+14 days) after the vaccination at Visit 1. Since the timeframe between Visit  1 and Visit  2 
(inclusive) will be captured in the diary card, the MA will be used to collect SAE and  MAAE  data from Visi t 2 to TC2.  
 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 19 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 20 of 82 List of Abbreviations 
µg micro gram (s) 
Ab antibody 
ACIP Advisory Committee on Immunization Practices  
AE adverse event  
  
AR adverse reaction  
CBER Center for Biologics Evaluation and Research  
CDM  Clinical Data Management  
CFU colony - forming unit  
CI confidence interval 
C&MQO  Clinical and Medical Quality Operations 
CRA Clinical Research Associate 
CRF electronic case report form 
CTA clinical trial agreement  
CTL  Clinical Team Leader  
D day 
EDC  electronic data capture  
eSAE  electronic Serious Adverse Event (Form)  
FAS Full Analysis Set 
FDA  Food and Drug Administration  
FVFS first visit, first subject 
FVLS first visit, last subject 
GBS  Guillain-Barré syndrome 
GCI Global Clinical Immunology 
GCP  Good Clinical Practice  
GMT  geometric mean titer 
GMTR  geometric mean titer ratio 
GPV  Global PharmacoVigilance  
HCP  health care provider  
hSBA serum bactericidal assay using human complement  
IATA  International Air Transport Association  
ICF inform ed consent form  
ICH International Conference on Harmonisation  
IEC Independent Ethics Committee  
IgG immunoglobulin G  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 20 of 83

Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 21 of 82 IM intramuscular (ly) 
IMD invasive meningococcal disease  
IOM  Institute of Medicine  
IRB Institutional Review Board  
ITP idiopathic  thrombocytopenic  purpura  
IWRS interactive web response system  
LCLS last contact, last subject  
LLOQ  lower limit of quantita tion 
LLT lowest level term  
MA memory aid  
MAAE  medically -attended adverse event  
MCV meningococcal conjugate vaccine  
MCV4  quadrivale nt meningococcal conjugate vaccine  
MedDRA  Medical Dictionary for Regulatory Activities  
mL milliliter (s) 
N. Neisseria  
NSAID  non-steroidal anti-inflammatory drug  
PPAS  Per-Protocol  Analysis S et 
PS polysaccharide 
PSO Product Safety Officer  
R&D  Research  and Development 
RCDC reverse cumulative distribution curve  
RMO Responsible Medical Officer  
rSBA serum bactericidal assay using rabbit complement  
SAE  serious adverse event  
SafAS  Safety Analysis S et 
SAP statistical analysis plan  
SMT Safety Management  Team 
TMF Trial Master F ile 
UAR  unexpected adverse reaction  
ULOQ  upper limit of quantita tion 
UTN  Universal Trial Number  
WHO  World Health Organization  
 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 21 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 22 of 82 1 Introduction 
1.1 Background 
This trial (MET35) will evaluate the immunogenicity and safety of a single dose of the 
quadrivalent Meningococcal Polysaccharide (serogroups A, C,  Y, and W) Tetanus Toxoid 
Conjugate V accine (hereafter referred to as MenACYW conjugate vaccine) in children 2 to 
9 years of age. The purpose of the MET35 trial is to demonstrate that the immunogenicity and 
safety profiles of the MenACYW conjugate vaccine are comparable with those of the MENVEO® 
in this age group. 
Invasive meningococcal disease (IMD)  is a serious illness caused by the bacterium Neisseria 
meningitidis (N. meningitidis) , a Gram -negative diplococcus found exclusively  in humans. 
Symptoms may include intense headache, fever, nausea, vomiting, photophobia, stiff neck, 
lethargy, myalgia, and a characteristic petechial rash  (1). At least 12 different meningococcal 
serogroups have  been classified based on the immunochemistry of the capsular polysaccharides 
(PS). Som e strains are more lik ely than others to cause infection  (1) (2) (3). Worldwide, most 
cases of menin gococcal disease are caused by serogroups A, B, C, X, Y, and W  (2) (3) (4). 
Serogroup B is responsible for endemic disease and some outbreaks, while serogroup C is 
responsible for large outbreaks  (5). Serogroup A remains the main cause of epidemics in the 
world and is especially dominant in Africa and Asia. Serogroup W has been observed in Africa, 
as well as the United Kingdom, in residents who participated in the Hajj pilgrimage to the Kingdom of Saudi Arabia  (4) (6) (7) and more recently in Chile  (8), Turkey  (9) (10), China 
(11) (12), Argentina  (13), Brazil  (14)  (15) , and other parts of the world. Serogroup X causes 
substantial meningococcal disease in parts of Africa, but rarely causes disease in other parts of the world  (2) (16). Serogroup Y has not been associated with outbreaks, but the frequency with which 
it causes sporadic cases has gradually increased in the US and more recently in Canada and Europe  (17) (18) (19). The Y serogroup is commonly associated with meningococcal pneumonia, 
particularly in older adults ≥ 65 years of age  (20) . Outbreaks of serogroup B meningococcal 
disease have also been reported on college campuses in the US during the last five -year period; a 
prolonged outbreak of serogroup B on a university campus in Ohio  from 2008 – 2010 and 
2 universities in New Jersey and California in 2013 (21) (22).  
The epidemiology of N . meningitidis  can be described as complex, unpredic table, geo graphically 
variable, and changing over time. Meningococcal disease occurs worldwide in both endemic and 
epidemic forms with seasonal variation.  In Europe, the incidence rate of IMD has remained stable 
over the last 5 to 10 years, with the highes t peak occurrin g in the population less than 4 years of 
age and a smaller peak i n the 15 to 19 year old group. The highest incidence rate in Europe is 
caused by serogroup B, followed by C  (23). The highest proportion of meningococcal cases was 
due to serogroup B in the population under 5 years of age. The highest proportion of serogroup C cases was observed in the population 25 to 44 years of age while the proportion of serogroup Y cases was highest in the population aged 65 years and above. Surveillance data from England and Wales showed an increase in endemic meningococcal serogroup W disease across all age groups, accounting for 15% of all IMD cases in 2013 - 2014 compared with an average of 1% to 2% of all 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 22 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 23 of 82 IMD cases in earlier years  (24). A gradual increase in serog roup Y IMD has also been recently 
reported in Swede n during 2005 – 2012 (25) (26). N early 50% of all IMD was caused by 
serogroup Y in 2012 (25). Similarly, an increase in t he proportion of I MD caused by serogroup Y 
has been observed in other Scandinavian countries, accounting for 31% in Norway in 2009 - 2010 
and 38% in Finland in 2010 (27).  
In the US, the incidence rate of IMD was 0.14 per 100,000 in all ages; 0.83 per 100,000 in infants less than 1 year; 0.62 per 100,000 in toddlers 1 year of age; 0.27 per 100,000 in children 2 to 4 years of age; and 0.02 per 100,000 in children 5 to 17 years of age in 2013. The age specific incidence rate per 100,000 was 0.08 in adults 50 to 64 years of age, 0.03 in adults 65 to 74 years of age, 0.14 in adults 75 to 84 years o f age, and 0.43 in adults 85 years of age and older in 2013 
(28).  
The goal for MenACYW conjugate vaccine is to provide broad protection against IMD caused by serogroups A, C, Y, and W in all age groups including children as young as 6 weeks of age,  
adolescents, and adults 56  years of age and older. 
1.2 Background of the Investigational Product  
1.2.1 Non-clinical Safety  
 
 
 
 
 
 
 
1.2.2 Clinical 
The MenACYW conjugate vaccine formulation was finalized based on data provided by 2 studies: MET28, a Phase I study in infants, toddlers, and adults 18 to 55 years of age; and MET32, a Phase I/II study in toddlers. 
The formulation has been evaluated in over 1639 subjects (infants, toddlers, adolescen ts, and 
adults > 55 years of age) in completed studies MET39, MET44 , MET50, and MET54. 
MenACYW conjugate vaccine is also being evaluated in an ongoing Phase III study (MET56 in 
adolescents and adults). The relevant  Phase II studies are discussed below.   
MenACYW conjugate vaccine was found to be well tolerated and no unanticipated or new significant safety concerns have been identified in the clinical trials completed to date  or in the 
ongoing MET56 study. 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 23 of 83

Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 24 of 82 1.2.2.1 Study MET39 (Phase II)  
MET39 was a Phase II, randomi zed, open- label, multi-center study conducted in the US for which 
580 healthy subjects from 2 to 15 months of age were enrolled. This study evaluated the optimal 
vaccination schedule in the infant/toddler population. Subjects in Group 1 through Group 4 rec eived 1, 2, or 3 primary doses plus an additional dose of the MenACYW conjugate 
vaccine in the second year of life, concomitantly with routine pediatric vaccines at several 
different vaccination schedules. Subjects in Group 5 received 1 dose of the MenACYW conjugate vaccine concomitantly with routine pediatric vaccines.  The routine pediatric vaccines given 
concomitantly with MenACYW conjugate vaccine at various schedules included Prevnar
® or 
Prevnar 13 vaccine, Pentacel vaccine, ROTARIX® or R otaTeq vaccine, hepatitis B vaccine,  
M-M-R II vaccine, and VARIVAX vaccine . 
Immunogenicity  
After the primary series consisting of 1, 2, or 3 doses of MenACYW conjugate vaccine, protective serum bactericidal assay using human complement (hSBA) threshold titers of ≥ 1:8 were attained by > 88% of subjects for serogroup C and by 62% to 74% for serogroup A. For serogroups Y and W, ≥ 90% achieved t he threshold titer af ter 3 doses, 75% to 84% after 2 doses, but only 25% after 
a single dose administered at 6  months of age.  
After an additional dose of MenACYW conjugate vaccine in the second year of life (12 or 15 months), between 91% and 100% of the s ubjects achieved the protective threshold regardless 
of the number of doses they received in the first year of life 
Safety  
MenACYW conjugate vaccine was well  tolerated in infants and toddlers regardless of the 
immunization schedule and the number of doses administered. Safety results were comparable to 
those seen in control group subjects regardless of the immunization schedule and the number of doses administered. The safety profile of the licensed vaccines given concomitantly with MenACYW conjugate vaccine was similar to that of the licensed vaccines given concomitantly without MenACYW conjugate vaccine. 
No deaths occurred within 30 days. There were 2 subjects in Group 4 who died during the study, 
1 as a result of hypoxic ischemic encephalopathy which star ted 96 days after the 6-month 
vaccination and 1 as a result of non- accidental head trauma 36 days after the 12 -month 
vaccination. These events were considered by the Investigator as unrelated to study vaccine. There were 2 other subjects who discontinued the study due to a  serious adverse event  (SAE ) and 
the receipt of intravenous immunoglobulin treatment: 1 subject in Group 2 with Kawasaki disease, 106  days after the 6 -month vaccination; and 1 subject in Group 3 with middle lobe 
pneumonia and Kawasaki disease, 50 and 52 days, respectively, after the 4 -month vaccinations. 
One other subject in Group 4 was discontinued due to a non- serious adverse event (AE) (viral 
rash 1  day after the 6-month vaccinations). None of these AEs leading to discontinuation were 
considered by the Investigator as related to the vaccine. There were no related SAEs during this 
study. 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 24 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 25 of 82 1.2.2.2 Study MET44 (Phase II)  
MET44 was a Phase II, randomized, open-label (the laboratory technicians were blinded to group 
assignment), multi-center study cond ucted in the US. This study evaluated the im munogenicity 
and safety profiles of a single dose of MenACYW conjugate vaccine when administered to adults 56 years of age and older. A total of 301 subjects aged 56 years and older on the day of enrollment were randomized to receive a single dose of MenACYW conjugate vaccine or Menomune
® - A/C/Y/W -135 ; each group was stratified according to age into 2 subsets (subjects 
56 to 64 years of age and subjects ≥ 65 years of age). 
Immunogenicity  
The proportions of subjects with hSBA titers ≥ 1:8 obtained after MenACYW conjugate vaccine 
administration (Group 1) for serogroups A and C were comparable to, or for serogroups Y and W 
higher than, those obtained after Menomune® – A/C/Y/W -135 administration (Group 2): 93.8% in 
Group 1 and 85.1% in Group 2 for serogroup A; 74.9% in Group 1 and 62.8% in Group 2 for serog roup C; 80.5% in Group 1 and 59.6% in Group 2 for serogroup Y; 79.5% in Group 1 and 
60.6% in Group 2 for serogroup W. 
Within each group of those who received MenACYW conjugate vaccine or 
Menomune
®-A/C/Y/W -135, the proportions of subjects with hSBA titers ≥ 1:8 were comparable 
between the subset of subjects 56 to 64 years  of age and the subset ≥ 65 years of age, for all 
serogroups. 
The hSBA geometric mean titers (GMTs) after MenACYW conjugate vaccine administration for 
serogroups A and W were comparable to, or for serogroups C and Y higher than, those after 
Menomune® - A/C/Y/W -135 administration. Responses with SBA using baby rabbit complement 
(rSBA) in general demonstrated the same trend as with hSBA . 
Safety  
Vaccination with MenACYW conjugate vaccine or Menomune® - A/C/Y/W -135 among adults 
56 years of age and older was found to be well tolerated, with no safety concerns identified. There 
were no immediate unsolicited AEs/reactions reported in either group. There were no deaths, 
SAEs or AEs that l ed to study discontinuation reported during the study. 
The safety profile of the vaccine s when compared by subject age was generally comparable 
between both age groups, with no clinical impact in the differences observed. In general, no increase in reactog enicity was observed in the older vaccine recipients as compared to the 
younger cohort in this study. 
1.2.2.3 Study MET50 (Phase II)  
MET50 was a Phase II, randomized, open- label, parallel -group, controlled, multi- center trial 
conducted in the US. This trial evaluated the immunogenicity and safety profile of a single dose of MenACYW conjugate vaccine when given alone compared to that of the licensed vaccine MENVO
® and when given concomitantly with Adacel® (Tetanus, diphtheria, acellular pertussis 
[Tdap] vaccine) and  GARDASIL® (human papilloma virus [HPV] vaccine) in healthy, 
meningococcal vaccine-naïve adolescents 10 to 17 years of age. Subjects in Group 1 received a single dose of MenACYW conjugate vaccine, subjects in Group 2 received a single dose of 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 25 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 26 of 82 MENVEO®, subj ects in Group 3 received a single dose each of MenACYW conjugate vaccine 
and Tdap vaccine and a total of 3 doses of HPV vaccine (Dose 1 on D0, Dose 2 and Dose 3 were 
given 2 and 6 months, respectively, after Dose 1), subject in Group 4 received  a single do se of 
Tdap vaccine and 3 doses of HPV vaccine on the same schedule as Group  3.  
Safety  
Vaccination with MenACYW conjugate vaccine among adolescents was found to be safe with no safety concerns identified when given alone or concomitantly with Tdap and HPV vaccines. The MenACYW conjugate vaccine was well tolerated with no immediate hypersensitivity reactions and no related SAEs. 
The safety profile of MenACYW conjugate vaccine was comparable to that of the licensed 
vaccine MENVEO
® when given alone, while the systemic reactogenicity was found to be higher 
when MenACYW conjugate vaccine was given with Tdap and HPV vaccines. However, reactogenicity remained comparable to that observed with the control Group 4, when the licensed concomitant vaccines were given wit hout MenACYW conjugate vaccine. 
The safety profiles of the concomitant licensed vaccines were comparable when administered with or without MenACYW conjugate vaccine.  
No new clinically important findings were identified with administration of the MenACYW 
conjugate vaccine.  
1.2.2.4 Study MET54 (Phase II)  
MET5 4 was a Phase II, randomized, open- label,  active-controlled, multi-center study conducted 
in Europe (Finland). This study evaluated the immunogenicity and safety profile of a single dose of MenACYW conjugate vac cine when given alone in healthy, meningococcal- vaccine naïve 
toddlers compared to that of the licensed vaccine Nimenrix
®. A total of 200 meningococcal 
vaccine naïve subjects aged 12 to 23 months on the day of enrollment were randomized to 1 of 2 groups. Group 1 received a single dose of MenACYW conjugate vaccine and Group 2 received a single dose of Nimenrix
®. 
Immunogenicity  
Antibody responses to the antigens (serogroups A, C, Y, and W) were evaluated by serum bactericidal assay using rSBA and hSBA. MenACYW conjugate vaccine immune responses evaluated by rSBA and hSBA were generally comparable to Nimenrix
® immune responses with 
some variation by serogroup: 
rSBA 
Most subjects had rSBA titers ≥ 1:128 at D30. The percentages after MenACYW conjugate 
vaccine wer e similar (100.0% [91/91] for serogroups A, Y, and W) or numerically higher 
(100.0% [91/91] for serogroup C) compared to Nimenrix® (100.0% [86/86] for serogroups A, Y, 
and W and 94.2% [81/86] for serogroup C). At D30, most subjects in both groups demonstrated an rSBA vaccine seroresponse as defined in the SAP and as defined in the protocol. The percentage of subjects with any rSBA vaccine seroresponse by either definition for serogroup A was numerically lower after MenACYW conjugate vaccine (91.2% [83/91]) than Nimenrix
® 
(98.8% [85/86]) and the percentages of subjects with any rSBA vaccine seroresponse by either 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 26 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 27 of 82 definition were similar or comparable between the 2 groups for serogroups C, Y, and W (all 
> 96%). 
hSBA 
Most subjects in both groups had hSBA titers ≥ 1:8 at D30: the percentages after MenACYW 
conjugate vaccine for serogroups A, Y, and W (ranging from 97.8% [89/91] to 98.9% [90/91]) 
were comparable to those after Nimenrix® (ranging from 91.9% [79/86] to 100.0% [86/86]). The 
percentage of subjects with  hSBA titers ≥  1:8 for serogroup C was higher after MenACYW 
conjugate vaccine (100.0% [91/91]) than after Nimenrix® (89.5% [77/86]). At D30, most subjects 
in both groups demonstrated an hSBA vaccine seroresponse. The percentage of subjects with an hSBA vac cine seroresponse for serogroups A, Y, and W was comparable in both groups (ranging 
from 96.7% [87/90] to 98.9% [90/91] after MenACYW conjugate vaccine and from 91.9% [79/86] to 98.8% [85/86] after Nimenrix
®). The percentage of subjects with an hSBA vaccine 
seroresponse for serogroup C was higher after MenACYW conjugate vaccine (100.0% [91/91]) than after Nimenrix
® (86.0% [74/86]). 
Safety  
Overall, vaccination with MenACYW conjugate vaccine among toddlers aged 12 to 23 months was found to be safe with no saf ety concerns identified. The MenACYW conjugate vaccine was 
well tolerated with no immediate AEs or ARs, no discontinuations due to an SAE or other AE, and no related SAEs. 
The safety profile of MenACYW conjugate vaccine was comparable to that of the licensed 
vaccine, Nimenrix
®. 
No new clinically important findings were identified with administration of the MenACYW conjugate vaccine. 
1.3 Potential Benefits and Risks  
1.3.1 Potential Benefits to Subjects  
MenACYW conjugate vaccine is an investigational vaccine that is undergoing active clinical investigation. There may be no direct benefit from receiving the MenACYW conjugate vaccine. 
However, based on the data generated from previous studies, the immunogenicity profile of the MenACYW conjugate vaccine in different age gr oups shows that the majority of subjects 
developed  seroprotective levels of antibodies after vaccination. T he safety evaluation indicates 
that the vaccine is well -tolerated , and no safety issues have been detected to date. In all, the data 
support further evaluation of the MenACYW conjugate vaccine in humans. 
Subjects who receive M ENVEO
® will likely be protected against meningococcal disease caused 
by N. meningitidis  serogroups A, C, Y, and W. 
As with any vaccine,  MenACYW conjugate vaccine and M ENVEO® may n ot protect 100% of 
individuals against the diseases they are designed to prevent.  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 27 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 28 of 82 1.3.2 Potential Risks to Subjects  
Like other vaccines, MenACYW conjugate vaccine or MENVEO® may cause injection site 
reactions such as pain, swelling, and erythema, or certain systemic events such as fever, headache, 
malaise, and myalgia. Common reactions following administration of MENVEO® in children 2 
through 10 years of age also include induration at the injection site, irritability, and sleepiness. There may be a rare possibili ty of an allergic reaction, which could be severe. There may also be a 
risk of febrile convulsion in some children who experience high fever. There may be other risks for MenACYW conjugate vaccine that  are not yet known. 
 
 
 
 
Importantly, no similar cases have 
been reported following the administration  of MenACYW conjugate vaccine in any other trials.  
Guillain -Barré syndrome (GBS) has been reported mostly in persons aged 11 to 19 years who had 
symptom onset within 6 weeks of administration of a US licensed meningococcal conjugate 
vaccine (29). A retrospective cohort study carried out in the US using healthcare claims data found no evidence of increase d GBS risk associated with the use of that vaccine. The study was 
able to exclude all but relatively small incremental risks  (30).  
A review by the Institute of Medicine (IOM) found inadequate evidence to accept or reject a causal relationship between tetanus toxoid containing vaccines and GBS  (31). The IOM found 
evidence for a causal relation between tetanus toxoid -containing vaccines and brachial neuritis 
(32). Arthus reactions are rarely reported after vaccination and can occur after tetanus toxoid -
containing vac cines  (33).  
No occurrences of GBS, brachial neuritis, or Arthus reaction have been reported with the use of 
MenACYW conjugate vaccine in the completed clinical trials.  
The risk of vasovagal syncope exists after any vaccination in the adolescent age group, although it has not been specifically reported in the age group under study as part of this protocol  (34). 
Syncope, sometimes resulting in falling injury associ ated with seizur e-like movements, has been 
reported following vaccination with the MENVEO
®. A few cases of immediate vasovagal -like 
response or syncope have been observed in adolescent subjects who had received MenACYW conjugate vaccine. 
The potential risks associated wit h blood drawing include local pain, bruising, and, rarely, 
fainting. The potential risk listed here are not exhaustive. Refer to the MENVEO
® package insert (35) and 
the Investigator’s Brochure of the investigational vaccine  for additional information regarding the 
potential risks.  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 28 of 83

Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 29 of 82 1.4 Rationale  for the Trial 
The MenACYW conjugate vaccine is desig ned for the immunization of individuals of all ages 
(infants 6 weeks of age and older through and including older adults > 65 years of age) against 
IMD. The purpose of the vaccine is to provide broad coverage against circulating meningococcal strains from  serogroups A , C, Y, and W. Compared to a previous Sanofi Pasteur meningococcal 
conjugate vaccine , Menactra
®, the MenACYW conjugate vaccine is prepared using tetanus toxoid 
as the carrier protein. Conjugation of polysaccharide antigens to a protein carrier can induce T-cell-dependent immune responses, which are anticipated to give rise to higher antibody titers, 
longer duration of the immune response, and enhanced immunologic memory that allows for a 
booster response . 
Meningococcal polysaccharide vaccines have two important limitations: a) the antibody response 
is age- dependent, with infants giving the poorest response; and b) polysaccharides alone are T -cell 
independent immunogens, and therefore no anamnestic response is seen. The immunogenicity of polysaccharide vaccines in infants and children has been shown to be improved by conjugating the polysaccharides to protein carriers. Among the key advantages expected of the tetanus carrier is improved immunogenicity in infants and older adults. Pre -clinical studi es using a mouse model 
and investigating different carriers, showed significant levels of polysaccharide -specific total 
immunoglobulin G (IgG) and bactericidal responses in response to the formulations with tetanus toxoid as a carrier. Early Phase I/II tri als including those with the final formulation (MET39 and 
MET44) showed the potential of the candidate vaccine as a very good immunogen in all age groups, including young infants and older adults. The MenACYW conjugate vaccine was found to be immunogenic and well tolerated; it did not raise any safety concerns in the above trials using the final formulation or in the earlier trials . 
The purpose of MET35 is to demonstrate that the immunogenicity profile  of a single dose of the 
MenACYW conjugate vaccine in ch ildren 2 to 9 years of age is comparable with MENVEO
®, a 
US licensed quadrivalent diphtheria CRM 197 protein conjugate meningococcal vaccine, and 
describe the safety profiles of both vaccines. 
2 Trial Objectives  
2.1 Primary Objective  
To demonstrate the non- inferi ority of the vaccine seroresponse to meningococcal serogroups A, 
C, Y, and W following the administration of a single dose of MenACYW conjugate vaccine 
compared to that observed following the administration of a single dose of MENVEO® in children 
aged 2 to 9 years  
The endpoints for the primary objective are presented in  Section 9.1. 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 29 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 30 of 82 2.2 Secondary Objective s 
1) To compare the hSBA antibody GMT s of meningococcal serogroups A, C, Y, and W 
following the administration of MenACYW conjugate vaccine to those observed following 
the administration of MENVEO® in children aged 2 to 9 years  of age 
2) To evaluate the hSBA antibody GMT s of meningococcal serogroups A, C, Y, and W 
following the administration of MenACYW conjugate vaccine and those observed following the administration of MENVEO
® in children 2 to 5 years of age, and in children 6 to 9 years 
of age, respectively  
3) To evaluate the hSBA vaccine seroresponse to meningococcal serogroups A, C, Y, an d W 
before and 30 days (+14 days) post- vaccination  in children 2 to 5 years of age, and in 
children 6 to 9  years of age, respectively  
The endpoints for the secondary objectives are presented in  Section 9.2.  
2.3 Observational Objectives 
Immunogenicity  
1) To describe the antibody titers against  meningococcal serogroups A, C, Y, and W measured 
by hSBA before and 30 days (+14 days) after vaccination with MenACYW conjugate vaccine 
or MENVEO® 
2) To describe the antibody titers against meningococcal serogroups A, C, Y, and W measured 
by rSBA before and 30 days (+14 days) after vaccination with MenACYW conjugate vaccine 
or MENVEO® in a subset of subjects 
Safety  
To describe the safety profile of MenACYW conjugate vaccine and that of the licensed MENVEO
® 
The endpoints for the observational objectives are presented in  Section 9.3.1.1 and  
Section 9.3.2.2, for  immunogenicity and safety, respe ctively . 
3 Investigators and Trial Organization 
This trial will be conducted in approximately 40 centers in  the USA  and Puerto Rico. The 
Principal Investigators and any sub- investigators at the individual sites will be coordinated by one 
Coordinating Investigator. Details of the trial centers, the Investigators at each center, and the Coordinating Investigator are provided in the “List of Investigators and Centers Involved in the Trial ” document. 
An internal Safety Management T eam (SMT) will perform a blinded safety analysis on safety 
data after vaccination.  
The Sponsor’s Responsible Medical Officer (RMO), the person authorized to sign this protocol 
and any amendments on behalf of the Sponsor, is  , , Clinical Team Leader.  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 30 of 83

Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 31 of 82 4 Independent Ethics Committee / Institutional Review Board 
Before the investigational product can be shipped to the investigational site and before the 
inclusion of the first subject, this proto col, the informed consent form(s) (ICF s), assent form(s) , 
subject recruitment procedures, and any other written information to be provided to subjects must be approved by, and / or receive favorable opinion from, the appropriate Independent Ethics 
Committee (IEC) or Institutional Review Board (IRB).  
In accordance with Good Clinical Practice (GCP) and local regulations, each Investigator and  / or 
the Sponsor are responsible for obtaining this approval and / or favorable opinion before the start 
of the trial.  If the protocol is subsequently amended, approval must be re-obtained for each 
substantial amendment. Copies of these approvals, along with information on the type, version number, and date of document, and the date of approval, must be forwarded by the I nvestigator to 
the Sponsor together with the composition of the IEC / IRB (the names and qualifications of the 
members attending and voting at the meetings). 
The Investigator and Sponsor will submit written summaries of the status of the trial to the IEC  / 
IRB annually, or more frequently if requested. All SAEs  occurring during the trial that are related 
to vaccination will be reported by the Investigator to the IEC  / IRB, according to the IEC / IRB 
policy. 
5 Investigational Plan 
5.1 Description of the Overall Trial Design and Plan  
5.1.1 Trial Design  
This is a Phase III, modified double-blind, randomized, parallel-group, active-controlled, multi-
center trial to evaluate the immunogenicity and describe the safety of MenACYW conjugate 
vaccine compared to the MENVEO® in healthy children 2 to 9 years of age in the U nited States 
and Puerto Rico. 
Healthy, meningococcal- vaccine naïve children aged 2 to 9 years will be randomized in a 1:1 ratio 
as follows: 
• Group 1: MenACYW conjugate vaccine: N = 500 
Group 1a:      250 children 2 to 5 years of agea 
Group 1b:      250 children 6 to 9 years of ageb 
• Group 2: MENVEO®:     N = 500 
Group 2a:      250 children 2 to 5 years of agea 
Group 2b:      250 children 6 to 9 years of ageb 
                                                 
a  “2 to 5 years of age” means from the day of the 2nd birthday to the day before the 6th birthday  
b  “6 to 9 years of age” means from the day of the 6th birth day to the day before the 10th birthday  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 31 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 32 of 82 All subjects will provide blood samples for immunogenicity assessment at baseline (pre-
vaccination) and at 30 to 44  days after vaccination.  
Solicited AE  information will be collected for 7 days after vaccination; unsolicited AE 
information will be collected from Visit 1 (Day [D] 0) to Visit 2 (D30 [+14 days]) and SAE  
information   will be collected throughout the 
study period from D0 through D180 (+14 days) after vaccination. 
Medically -attended adverse event s (MAAE s) will be collected throughout the study from Vi sit 1 
through Visit 2 (as part of the collection of unsolicited AE information) and from Visit 2 through 
D180 (+14 days) (as MAAEs) . 
5.1.2 Justification of the Trial Design  
 
MET35 is a study that w ill be conducted as part of 
the Phase III development of the MenACYW conjugate vaccine in which  the vaccine candidate 
will be evaluated in the age group of 2 to 9 year old children. This study is designed to evaluate 
immunogenicity responses and safety profiles following the administration of a single dose of the MenACYW conjugate vaccine compar ed to the r esponses observed after a single dose of a 
licensed quadrivalent meningococcal vaccine (MENVEO
®) in this population. Enrollment in the 
study will be stratified in 2 age groups, 2 to 5 years of age and 6 to 9 years of age. Age stratified 
data will be p resented in a descriptive fashion. Data in the 2 to 9 year age range are needed as part 
of the overall data for key age groups typically required by the Center for Biologics Evaluation and Research ( CBER) in the context of achieving licensure with a broad age indication.  
In the US, meningococcal vaccination is not routinely recommended for children ≤ 10  years of 
age, however the vaccination is recommended for individuals at risk of disease. ACIP recommends routine administration of a quadrivalent meningococcal conjugate vaccine (MCV4) for all persons aged 11 through 18 years. A single dose of vaccine should be administered at age 
11 or 12 years, and a booster dose should be administered at age 16 years. The minimum interval between doses of MCV4 is 8 weeks. Children who receive meningococcal conjugate containing 
vaccines before age 10 years should receive the routinely recommended dose at age 11 or 
12 years and a booster dose at age 16  years (36).  
The selection of MENVEO
® as a comparator will contribute towards the total database of subjects 
that is compared to the competitor’s product in the final dossier and will be beneficial for the Food and Drug Administration (FDA) review of the file, as MENVEO
® is one of the quadrivalent 
meningococcal conjugate vaccines licensed in the US . 
5.1.3 Trial Plan  
A schedule of assessments and study vaccinations is provided in the Table of Study Procedures.  
Vaccination 
All subjects will receive a single dose of either MenACYW conjugate vaccine or MENVEO® at 
Visit 1 ( D0). 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 32 of 83

Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 33 of 82 Blood Sampling 
All subjects will provide a pre- vaccination blood sample  at D0 and a post- vaccination sample at 
Visit 2 (30 to 44 days a fter the vaccination at Visit 1). 
Antibodies to meningococcal serogroups A, C, Y, and W antigens will be measured by hSBA for 
all subjects, and by rSBA for a subset of subjects. 
Table 5.1: Testing strategy for  N meningitidis  serogroups A, C, Y, and W 
 ACYW serogroups tested by 
hSBA* 
(all subjects)  ACYW serogroups tested by 
rSBA† 
(subset) 
Group 1   
 Group 1a (2 to 5 years old)  250 100 
 Group 1b (6 to 9 years old)  250 100 
Group 2   
 Group 2a (2 to 5 years ol d) 250 100 
 Group 2b (6 to 9 years old)  250 100 
* hSBA: serum bactericidal assay using human complement 
† rSBA: serum bactericidal assay using baby rabbit complement  
Collection of Safety Data  
• All subjects will be observed for 30 minutes after vaccination  and any unsolicited systemic 
AEs occurring during that time will be recorded as immediate unsolicited systemic AEs in the 
electronic case report form ( CRF ) (see Section 9.3.2.3.1) . 
• The subject ’s parent / guardian will record information in a diary card about solicited 
reactions from D0 to D07 after vaccination and unsolicited AEs from D0 to Visit 2. SAEs  will 
be reported throughout the duration of the trial. 
• The subject’s parent / guardian wil l record information only about possible SAEs and MAAEs 
in a memory aid (MA) from Visit 2 until the 6 -month (+14 days) telephone call. 
• In addition, the subject’s parent / guardian will be asked to notify the site immediately about 
potential SAEs at any tim e during the trial.  
• Staff will contact the subject’s parent / guardian by telephone on D08 (+ 2 days) to identify the 
occurrence of any SAE not yet reported and to remind them to complete the diary card up to 
Visit 2 and to bring it back at Visit 2. 
• The com pleted diary card will be reviewed with  the subject’s parent / guardian at Visit  2. 
• Staff will contact the subject’s parent / guardian by telephone at 6 months (+14 days) post-
vaccination to review the MA and identify the occurrence of any MAAEs as well as SAEs that may not have been reported. 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 33 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 34 of 82 5.1.4 Visit Procedures 
Medical procedures (examinations, injections, etc.) must be conducted by appropriately licensed 
or credentialed study site staff working within the scope of their license/credentials.  
Visit 1 (D0): In clusion, Randomization, Blood Sample, and Vaccination  
1) Give the subject and / or the  subject’s parent  / guardian information about the trial, answer any 
questions, obtain written informed consent and assent (as applicable) and give the subject’s parent / guardian  a signed copy of the ICF and a signed copy of the assent form (as 
applicable). 
2) Check inclusion and exclusion criteria for eligibility (s ee Section 5.2.4 a nd Section 5.2.5, 
respectively).  
3) Collect relevant demographic information. 
4) Perform urine pregnancy test (if applicable).  
5) Obtain verbal  medical history  about the subject . 
6) Conduct a history- directed physical examination, including temperature (a physical 
examination conducted during the same day as part of routine clinical care may be used for this purpose). 
7) Connect to the Interactive Web Response System ( IWRS)  for subject identification number 
and randomization (s ee Section 6.5 f or instructions).  
8) Obtain the first blood sample (5 milliliter [ mL]) (see Section 7 for  detai led instructions 
regarding the handling of blood samples). If attempts to obtain the first blood draw are unsuccessful ( no more than 3 attempts), then Visit 1 can be rescheduled to a later date at 
which point informed consent and inclusion/exclusion criter ia must be re- validated. If the 
first blood draw cannot be obtained, the subject will be withdrawn from the study without 
being vaccinated. 
9) Administer the appropriate study vaccine to the subject in the deltoid muscle . The vaccine 
must be administered on the side opposite to that of the blood sampling according to the study group: 
Group 1 = MenACYW conjugate vaccine  
Group 2 = MENVEO
®  
10) Observe the subject  for 30 minutes, and record any AE in the source document. 
11) Give the subject’s parent / guardian a diary card, a thermometer, and a ruler, and go over the 
instructions for their use.  
12) Remind the subject’s parent / guardian to expect a telephone call 8 days after Visit  1 and to 
bring back the d iary card when they return for Visit 2 at a specified date and time.  
13) Remind the subject’s parent / guardian to notify the site in case of an SAE. 
14) Complete the relevant CRF pages for this visit.  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 34 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 35 of 82 Telephone Call 1 ( D08 [+2 days] after Visit  1) 
Note : If D 08 falls on a weekend or a holiday, the telephone call may be made on the following 
business day.  If the subject’s parent / guardian is not available, the study staff should document 
the attempts to make contact.  
1) Record relevant information concerning the subject’s health status on the telephone contact 
form. If an SAE occurred, follow the instructions in Section 10 fo r reporting it.  
2) Remind the subject’s parent / guardian to do the following: 
• Complete the D0 to D0 7 pages of the diary card.  
• Complete the remaining pag es of the diary card, and bring them to Visit 2. 
• Notify the site in case of an SAE . 
Visit 2 (D30 [+ 14 days] after Visit  1): Collection of Safety Information and Blood Sample 
1) Review the pages of the diary card with the subject’s parent  / guardian, including any AEs,  
medications, or therapy t hat occurred since vaccination.  
2) Review the temporary contraindications for blood sampling (see  Section 5.2.8) . 
3) Obtain the second blood sample (see  Section 7 for  detailed instructions regarding the 
handling of blood samples). 
4) Give the subject’s parent / guardian an  MA.  
5) Complete the termination record of the CRF.  
6) If the subject’s parent / guardian does not return for Visit 2, and the diary card is not received 
at the site, site personnel will contact the subject’s parent / guardian by telephone. During the 
telephone call, the subject’s parent / guardian will be reminde d to return the diary card to the 
study site. Telephone calls will be documented on the Telephone / Interview Record. If the study personnel are unable to contact the subject’s parent / guardian with 3 attempts, the 
study personnel will follow instructions given in  Section 5.2.10. 
Safety Follow -up Telephone Call 2 (D180 [+14 days] after Visit 1): Collection of SAEs  and 
MAAEs  
Review the MA and ask the subject’s parent / guardian if the subject h as experienced any SAE in 
the time since vaccination  that has not been reported to the study personnel and / or MAAE. 
• If an SAE , , has occurred, follow the instructions in Section 10 for 
reporting it. 
• If an MAAE has occurred, follow the instructions in the Operating Guidelines. 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 35 of 83

Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 36 of 82 SAEs and AEs That Are Related to Vaccination or That Led to Discontinuation: 
At any time during the study, a subject who experiences an SAE or an AE must be followed if 
either  of the following is true: 
• The SAE or AE is considered by the Investigator to be related to vaccination, and is not 
resolved by the end of the subject’s participation in the trial 
• The subject has been discontinued fro m the trial because of the SAE or AE  
Any subject must be followed until the condition resolves, becomes stable, or becomes chronic. 
5.1.5 Planned Trial Calendar  
The following dates are approximate. The actual dates may differ as, for example, the trial will 
not start until all the appropriate regulatory and ethical approvals have been obtained. 
Planned trial period - FVFS (first visit, first subject) to LCLS (last contact, last subject) : 
17 Feb ruary  2017 to 10 October 2017. 
Planned inclusion period - FVFS to  FVLS (first visit, last subject ): 17 February 2017 to 
30 March  2017 
Planned primary vaccination period: 17 February  2017 – 30 March  2017 
Planned end of trial (LCLS) : 10 October 2017 
Planned date of preliminary  clinical study report: July 2018 
Planned date of f inal clinical study report: September 2018 
The safety follow-up Telephone C all 2 (6 months [+14 days] after Visit  1) of the last subject in 
either group is considered to be the end of the trial. 
5.1.6 Early Safety Data Review 
This trial will not include an early  review of safety data (i.e. no early safety review [s] of 
preliminary safety data occurring at pre-determined milestones defined in the protocol with pause 
in enrollment). However, it may be interrupted at any time if new data about the investigational product become available, and/or on advice of the Sponsor, the IECs/IRBs, or the governing regulatory authorities in the country where the trial is taking place.  
If the trial is prematurely terminated or suspended, the Sponsor will promptly inform the Investigator’s, the IECs/IRBs, and the regulatory authorities of the reason for the termination or suspension. If the trial is prematurely terminated for any reason, the Investigator will promptly inform the subjects’ parents / guardian and should assure appropriate therapy and follow-up. 
    
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 36 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 37 of 82 5.2 Enrollment and Retention of Trial Population  
5.2.1 Recruitment Procedures 
Before the start of the trial, the Investigator and / or study staff may contact the parent s / 
guardians of an appropriate pool of potential subjects and invite them to participate in the study. 
The site will ensure that any advertisements used to recruit subjects (e.g. letters, pamphlets, and 
posters ) are submitted to Sanofi Pasteur for review prior to submission to the IEC/ IRB for 
approval. 
In addition, a parent who brings a child to the trial site for a routine visit may  be invited to enroll 
the subject in the trial, if eligible. Subjects may also be recruited from the general population. 
5.2.2 Informed Consent Procedures 
Informed consent is the process by which a subject or a  subject ’s parent or guardian voluntarily 
confirms his or her willingness to participate / allow  his or her child to participate in a particular 
trial. Informed consent must be obtained before any study procedures are performed. The process 
is documented by means of a written, signed, and dated ICF. 
In this study, each subject as required by local regulations will sign a separate assent form. This 
form is to be used in addition to, not in place of, the ICF that is signed by the subject’s paren t / 
guardian. In accordance with GCP, prior to signing and dating the consent form, the subject  or parent / 
guardian must be informed by appropriate study personnel about all aspects of the trial that are 
relevant to making the decision to participate, and must have sufficient time and opportunity to ask any questions. Prior to signing the assent form, children as required by local regulations must  
also be informed by appropriate study personnel regarding aspects of the trial that are relevant to 
making the decision to participate and have sufficient  time and opportunity to ask any questions. 
A subject whose parent / guardian cannot read or write will not be included in the trial. A subject who is required to sign an assent form and cannot read or write will not be included in the trial. 
The actual ICF used at each center may differ, depending on local regulations and IEC / IRB 
requirements. However, all versions must contain the standard information found in the sample 
ICF provided by the Sponsor. Any change to the content of the ICF must be approved by the Sponsor and the IEC / IRB prior to the form being used. 
If new information becomes available that may be relevant to the subject’s or subject’s parent ’s / 
guardian ’s willingness to continue participation in the trial, this will be communicated to him  / her 
in a timely manner. Such information will be provided via a revised ICF or an addendum to the original ICF.  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 37 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 38 of 82 Informed consent forms will be provided in duplicate, or a photocopy of the signed consent will 
be made. The original will be kept by the Investigator, and the copy will be kept by the subject ’s 
parent / guardian. The assent forms will also be provided in duplicate, or a photocopy of the 
signed assent form will be made. The original will be kept by the Investigator, and the copy will 
be kept by the subject or subject’s parent / guardian. 
Documentation of the consent process should be recorded in the source documents. 
5.2.3 Screening Criteria  
There are no screening criteria other than the inclusion and exclu sion criteria.  
5.2.4 Inclusion Criteria  
An individual must fulfill all of the following criteria in order to be eligible for trial enrollment:  
1) Aged 2 to 9 years on the day of inclusiona 
2) Assent form has been signed and dated by the subject ( as required by local r egulations ) and 
informed consent form (ICF) has been signed and dated by the parent(s) or guardian 
3) Subject and parent  / guardian are able to attend all scheduled visits and to comply with all 
trial procedures.  
5.2.5 Exclusion Criteria  
An individual fulfilling any of the following criteria is to be excluded from trial enrollment: 
1) Subject is pregnant, or lactating, or of childbearing potential and not using an effective 
method of contraception or abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination. To be considered of non-childbearing potential, a female must be pre-menarche.
b 
2) Participation in the 4 weeks preceding the trial vaccination or planned participation during the present trial period in another clinical trial inves tigating a vaccine, drug, medical device, or 
medical procedure 
3) Receipt of any vaccine in the 4 weeks (28 days) preceding the trial vaccination or planned receipt of any vaccine prior to Visit 2 except for influenza vaccination, which may be received at least 2 weeks before or after the study investigational vaccines. Thi s exception 
includes monovalent, multivalent, live, and attenuated influenza vaccines  
                                                 
a  “2 to 9 years” means from the day of the 2nd birthday to the day before the 10th birthday  
b  Pre-menarche females will declare by themselves that they have not yet started menstruation. If a young female 
subject r eaches menarche during the study, then she is to be considered as a woman of childbearing potential from 
that time forward  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 38 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 39 of 82 4) Previous vaccination against meningococcal disease with either the trial vaccine or another 
vaccine (i.e., mono- or polyvalent, polysaccharide, or conjugate meningococcal vaccine 
containing serogroups A, C, Y, or W; or meningococcal B serogroup containing vaccine)  
5) Receipt of immune globulins, blood or blood-derived products in the past 3 months 
6) Known or suspected congenital or acquired immunodeficiency; or receipt of 
immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long- term systemic corticosteroid therapy (prednisone or 
equivalent for more than 2 consecutive weeks within the past 3 months) 
7) History of meningococcal infection, confirmed either clinically, serologically, or microbiologically  
8) At high risk for meningococcal infection during the trial (specifically, but not limited to, subjects with  persistent complement deficiency, with anatomic or functional asplenia, or 
subjects traveling to countries with high endemic or epidemic disease)  
9) Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction t o the vaccines used in the trial or to a vaccine containing any of the 
same substances
a 
10) Verbal report of thrombocytopenia, contraindicating intramuscular vaccination by the Investigator’s judgment 
11) Bleeding disorder, or receipt of anticoagulants in the 3 we eks preceding inclusion, 
contraindic ating intramuscular vaccination  in the Investigator’s opinion 
12) Personal history of Guillain -Barré  syndrome (GBS) 
13) Personal history of an Arthus- like reaction after vaccination with a tetanus toxoid -containing 
vaccine  
14) Chro nic illness that, in the opinion of the Investigator, is at a stage where it might interfere 
with trial conduct or completionb 
15) Moderate or severe acute illness /infection  (according to Investigator ’s judg ment) on the day 
of vaccination or febrile illness (temperature ≥ 100.4°F). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided  
16) Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw 
17) Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study 
If the subject has a primary physician who is not the Investigator, the site must  contact this 
physician with the parent’s / guardian ’s consent  to inf orm him / her of the subject’s participation 
                                                 
a  The components of the MenACYW conjugate vaccine are listed in  Section 6.1.1  and in the Investigator’s 
Brochure. The components of the MENVEO® vaccine are listed in Section 6.1.2.1  
b  Chronic illness may include, but is not lim ited to, cardiac disorders, renal disorders, auto -immune disorders, 
diabetes, psychomotor diseases, and known congenital or genetic diseases  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 39 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 40 of 82 in the study. In addition, the site should ask this primary physician to verify exclusion criteria 
relating to previous therapies, such as receipt of blood products or previous vaccines. 
5.2.6 Medical History  
Prior to  enrollment, subjects will be assessed for pre-existing conditions and illnesses, both past 
and ongoing. Any such conditions will be documented in the source document. Significant 
medical history (reported as diagnosis) including conditions for which the s ubject is or has been 
followed by a physician or conditions that could resume during the course of the study or lead to an SAE or to a repetitive outpatient care will be collected in the CRF. The significant medical 
history section of the CRF contains a co re list of body systems and disorders that could be used to 
prompt comprehensive reporting, as well as space for the reporting of specific conditions and illnesses.  
For each condition, the data collected will be limited to:  
• Diagnosis (this is preferable to  reporting signs and symptoms) 
• Presence or absence of the condition at enrollment  
The reporting of signs and symptoms is strongly discouraged. 
Dates, medications, and body systems are not to be recorded, and the information collected will not  
be coded. Its purpose is to assist in the later interpretation of safety data collected during the trial.  
5.2.7 Contraindications for Subsequent Vaccinations  
Not applicable since only one dose of vaccine will be administered in this trial. 
5.2.8 Contraindications for Subsequent Blood Samples  
Should a subject receive oral or injectable antibiotic therapy within 3  days prior to the second 
blood draw, the Investigator will postpone that blood draw until it has been 3 days (72hrs) since 
the subject last received oral or injectable anti biotic therapy. Postponement must still be within 
the timeframe for blood draw (30 to 44 days after vaccination at D0 ). If postponement would 
result in the sample collection falling outside of this timeframe, the blood sample should be collected without postponement, and it should be documented appropriately that the sample was taken less than 3  days after stopping antibiotic treatment.  
5.2.9 Conditions for Withdrawal 
Parents / guardians will  be informed that they have the right to withdraw their child from the t rial 
at any time.  A subject may be withdrawn from the study: 
• At the discretion of the Investigator or Sponsor due to safety concerns (withdrawal) without the permission of the subject’s parent / guardian  
• At the request of the subject or subject’s parent / guardian (dropout) 
 
 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 40 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 41 of 82 The following will result in automatic withdrawal or exclusion of a subject from the study: 
• Significant non-compliance with the protocol, based on the Investigator’s judgment 
The reason for a withdrawal or dropout should be clearly documented in the source documents 
and on the CRF.  
The Investigator must determine whether voluntary withdrawal is due to safety concerns (in 
which case, the reason for discontinuation will be noted as “SAE” or “other AE” as appropriate) or for another reas on. 
Withdrawn subjects will not be replaced. 
5.2.10 Lost to Follow- up Procedures  
In the case of subjects who fail to return for a follow-up examination, documented reasonable 
effort (i.e., documented telephone calls and certified mail) should be undertaken to loc ate or recall 
them, or at least to determine their health status while fully respecting their rights. These efforts should be documented in the CRF and in the source documents. 
5.2.11 Classification of Subjects Who Discontinue the Trial  
For any subject who discontinues the trial prior to completion, the most significant reason for 
early termination will be checked in the CRF . Reasons are listed below from the most significant 
to the least significant (refer to the CRF completion guidelines for additional details and 
examples) : 
• Serious adverse event:  To be used when a subject drops out of or is withdrawn from the 
study by the Investigator because of the occurrence of an SAE, as defined in Section 9.3.2.1. 
• Other adverse event:  To be used when a subject drops out of or is withdrawn from the study 
by the Investigator because of the occurrence of an AE other than an SAE, as defined in 
Section 9.3.2.1. 
• Non-compliance with protocol:  To be used when the Investigator withdraws a subject from 
the study because of failure to follow the protocol, including when it is retrospectively discovered that a subject did not fulfi ll the eligibility criteria. The Investigator will provide a 
comment as to the specific cause of non -compliance.  
• Lost to follow -up: To be used when the Investigator withdraws a subject from the study 
because of failure to establish contact, as outlined in  Section 5.2.10. The Investigator will 
provide  documentation that contact was attempted (i.e., return of unsigned certified letter 
receipt).  
• Voluntary withdrawal not due to an a dverse event:  To be used when a subject drops out 
of the study for any reason other than those listed above. 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 41 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 42 of 82 5.2.12 Follow-up of Discontinuations  
The site should complete all scheduled safety follow -ups and contact any subject who has 
prematurely terminated the trial because of an SAE, other type of AE, non-compliance with the 
protocol, or loss of eligibility, including definite contraindications. 
For subjects where the reason for early termination was lost to follow -up or if the subject 
withdrew informed consent and specified that they do not want to be contacted again and it is 
documented in the source document, the site will not attempt to obtain further safety information. For subjects where the reason for early termination is voluntary withdrawal, the site will attempt 
to contact them for the 6 -month follow-up, except if they specified that they do not want to be 
contacted again and it is documented in the source document. 
5.2.13 Follow-up and Reporting of Pregnancies  
Pregnancy is an exclusion criterion for enrollment in this study, but a subject could potentially 
become pregnant during her participation. In case of pregnancy and if at least one dose of the 
study vaccine has been administered, the subject will not be discontinued from the trial and will be followed for safety assessment (and may be followed for immunogenic ity assessment, if 
applicable).  
All pregnancy cases should be reported if they occurred during the study and during the 6 month follow up period, or if the start date of the pregnancy cannot be determined. To report the pregnancy case,  the Investigator must fill out a Pregnancy Reporting Form in the electronic data 
capture (EDC) system  and send it to the Sponsor within 1 month of identifying a pregnancy case.  
Study staff must then maintain contact with the subject to obtain information about the outcome—i.e., details about the delivery and the newborn, or about pregnancy termination—and must update the electronic  Pregnancy Reporting Form. This information should be provided to the Sponsor 
within 1 month  of delivery. 
Pregnancy itself is not considered an AE, but any complications during pregnancy are to be considered as AEs, and in some cases could be considered SAEs. Spontaneous abortions, fetal death, stillbirth, and congenital anomalies reported in the baby are always considered as SAEs, and the information should be provided to the Global PharmacoVigilance (GPV) Department 
regardless of when the SAE occurs (e.g., even after the end of the trial).  
5.3 Safety Emergency Call  
If, as per the Investigator’s judgment, a subject experiences a medical emergency, the Investigator may contact the Sponsor’s RMO for advice on trial related medical question or problem. If the RMO is not available, then the Investigator may contact the Call Center - available 2 4 hours a 
day, 7 days a week - that will forward all safety emergency calls to the appropriate primary or 
back -up Sanofi Pasteur contact, as needed. The toll- free contact information for the Call Center is 
provided in the Operating Guidelines. 
This process does not r eplace the need to report  an SAE. The investigator is still required to 
follow the protocol defined process for reporting SAEs to GPV (Please refer to  Section 10). 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 42 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 43 of 82 In case of e mergency code-breaking, the Investigator is required to follow the code-breaking 
procedures described in  Section 6.4.  
5.4 Modification of the Trial and Protocol  
Any amendments to this trial plan and protocol must be discussed with and approved by the 
Sponsor. If agreement is reached concerning the need for an amendment, it will be produced in writing by the Sponsor, and the amended version of the protocol will replace the earlier version. All substantial amendments , e.g., that affect the conduct of the trial or the safety of subjects, 
require IEC  / IRB approval, and must also be forwarded to regulatory authorities. 
An administrative  amendment to a protocol is one that modifies some administrative or logistical 
aspect of the trial but does not affect its design or objectives or have an impact on the subjects’ safety. Administrative changes do not require IEC / IRB approval; however, the IEC / IRB must be 
notified whenever one is made.  
The Investigator is responsible for ensuring that changes to an approved trial, during the period for which IEC / IRB approval has already been given, are not initiated without IEC / IRB review 
and approval, except to eliminate apparent immediate hazards t o subjects. 
5.5 Interruption of the Trial 
The trial may be discontinued if new data about the investigational product resulting from this or any other trials become available; or for administrative reasons; or on advice of the Sponsor, the Investigators, and / or the IECs  / IRBs. If the trial is prematurely terminated or suspended, the 
Sponsor shall promptly inform the Investigators, the regulatory authorities, and the IECs / IRBs of 
the reason for termination or suspension, as specified by the applicable regul atory requirements.  
The Investigator shall promptly inform the trial subjects and assure appropriate therapy and  / or 
follow-up for them. 
6 Vaccines Administered 
6.1 Identity of the Investigational Product 
6.1.1 Identity of Trial Product  
MenACYW conjugate vaccine:  Men ingococcal Polysaccharide ( Serogroups A, C, Y and W) 
Tetanus Toxoid Conjugate vaccine (Sanofi Pasteur Inc., Swiftwater, PA, USA) 
Form:    Liquid solution 
Dose:    0.5 mL  
Route:    IM 
Batch number:  To be determined 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 43 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 44 of 82 6.1.1.1 Composition  
Each 0.5 mL dose of MenACYW conjugate vaccine is formulated in sodium acetate buffered 
saline solution to contain the following ingredients : 
Meningococcal capsular polysaccharides:  
Serogroup A  ........................................................................................ 10 micrograms (µg ) 
Serogroup C ............................................................................................................... 10 µg  
Serogroup Y  ............................................................................................................... 10 µg  
Serogroup W  .............................................................................................................. 10 µg  
Tetanus toxoid protein carrier  approximately  ....................................................................... 65 µg  
6.1.1.2 Preparation and Administration  
MenACYW conjugate vaccine is supplied in single-dose vials (0.5 mL). 
Prior to administration, all study products must be inspected visually for cracks, broken seals, 
correct label content (see  Section 6.3.1),  and extraneous particulate matter and / or discoloration, 
whenever solution and container permit. If any of these conditions exists, the vaccine must not be administered. A replace ment dose is to be used, and the event is to be reported to the Sponsor. 
The rubber stopper should not be removed from any of the vaccine vials. 
The site of IM injection should be prepared with a suitable antiseptic prior to administration of 
one dose (0.5 mL) of MenACYW conjugate vaccine in the deltoid muscle of the arm. After 
vaccine administration, the used syringe and needle will be disposed of in accordance with currently established guidelines. 
Subjects must be kept under observation for 30 minutes after vaccination to ensure their safety, 
and any reactions during this period will be documented in the CRF. Appropriate medical 
equipment and emergency medications, including epinephrine (1:1000), must be available on site in the event of an anaphylactic or other immediate allergic reaction.  
6.1.1.3 Dose Selection and Timing  
All subjects in Group 1 will receive 1 dose of MenACYW conjugate vaccine on D0. 
6.1.2 Identity of Control Product  
MENVEO
®: Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria 
CRM 197 Conjugate Vaccine (Novartis Vaccines and Diagnostics S.r.1., Sovicille, Italy) 
Form:  Lyophilized powder and liquid components are combined to produce a 
 solution for intramuscular  injection  
Dose:  0.5 mL  
Route:  IM 
Batch number:  To be determined (control product will be supplied by the Sponsor) 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 44 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 45 of 82 6.1.2.1 Composition  
Each 0.5 mL dose of vaccine contains the following active ingredients: 
MenA oligosaccharide  ............................................................................................... 10 µg  
MenC oligosaccharide  ................................................................................................. 5 µg  
MenY oligosaccharide  ................................................................................................. 5 µg  
MenW-135 oligosaccharide  ......................................................................................... 5 µg  
CRM 197 protein carrier  ........................................................................................... 32.7 to 64.1 µg  
Other ingredients per 0.5 mL dose: residual formaldehyde ≤ 0.30 µg  
6.1.2.2 Preparation and Administration  
The MENVEO® is supplied in 2 vials, a lyophilized MenA conjugate vaccine component to be 
reconsti tuted with the accompanying MenCYW -135 liquid conjugate component. A single dose 
after reconstitution is 0.5 mL. 
See the MENVEO® package insert  (35).The procedures for administering the control product are 
the same as those described for the trial product in Section 6.1.1.2. 
6.1.2.3 Dose Selection and Timing  
All subjects in Group 2 will receive 1 dose of MENVEO® on D0. 
6.2 Identity of Other Product s 
Not applicable. 
6.3 Product Logistics  
6.3.1 Labeling and Packaging 
MenACYW conjugate vaccine will be supplied in single -dose vials, labeled and packaged 
according to national regulations. The information on the label and packaging will include: 
• Study code 
• Product name 
• Pharmaceutical form  
• Dosage 
• Storage conditions 
• Name of manufacturer 
• The statement: “Caution: New Drug – Limited by Federal Law to Investigational  
Use” 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 45 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 46 of 82 Commercial lots of MENVE O® (supplied in 2 vials that must be combined prior to administration 
to produce a single dose) will be supplied by the Sponsor, with the manufacturer’s labeling and 
packaging. 
6.3.2 Product Shipment, Storage, and Accountability  
6.3.2.1 Product Shipment  
The Clinical Log istics Coordinator or designee will contact the Investigator or a designee in order 
to determine the dates and times of delivery of products. 
Each vaccine shipment will include a temperature-monitoring device to verify maintenance of the 
cold chain during transit. On delivery of the product to the site, the person in charge of product receipt will follow the instructions given in the Operating Guidelines, including checking that the cold chain was maintained during shipment (i.e., verification of the temper ature recorders). If 
there is an indication that the cold chain was broken, this person should immediately quarantine the product, alert the Sanofi Pasteur  representative, and request authorization from Sanofi Pasteur  
to use the product. 
6.3.2.2 Product Storage  
The Investigator will be personally responsible for product management or will designate a staff 
member to assume this responsibility.  
At the site, products must be kept in a secure place with restricted access. Vaccines will be stored 
in a refrigerator at a  temperature ranging from +2°C to +8°C. The vaccines must not be frozen. 
The temperature must be monitored and documented (see the Operating Guidelines) for the entire time that the vaccine is at the trial site. In case of accidental freezing or disruption  of the cold 
chain, vaccines must not be administered and must be quarantined, and the Investigator or 
authorized designee should contact the Sanofi Pasteur  representative for further instructions.  
6.3.2.3 Product Accountability  
The person in charge of product management at the site will maintain records of product delivery 
to the trial site, product inventory at the site, the dose given to each subject, and the disposal of or return to the Sponsor of unused doses. 
The necessary information on the product labels is to be entered into the source document and the 
CRF . If applicable, information may also be entered into the subject’s vaccination card. 
The Sponsor’s monitoring staff will verify the trial site’s product accountability records against the record of admini stered doses in the CRFs and the communication from the IWRS  (if 
applicable). 
In case of any expected or potential shortage of product during the trial, the Investigator or an 
authorized designee should alert the Sanofi Pasteur representative as soon as possible, so that a shipment of extra doses can be arranged.  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 46 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 47 of 82 6.3.3 Replacement Doses 
If a replacement dose is required (e.g., because the vial broke or particulate matter was observed in 
the vial ), the site personnel must either connect to the IWRS to receive the new dose allocation, or 
follow the instructions given in the Operating Guidelines. 
6.3.4 Disposal of Unused Products  
Unused or wasted products will be either disposed of or returned to the Sponsor in accordance 
with the instructions in the Operating Guidelines. Product accountability will be verified throughout the trial period. 
6.3.5 Recall of Products  
If the Sponsor makes a decision to launch a retrieval procedure, the Investigator(s) will be 
informed of what needs to be done. 
6.4 Blinding and Code -breaking Procedures  
This trial is a modified double- blind  trial, which means that the subject , the subject’s parent / 
guardian, the Investigator, and other study personnel remain unaware of the treatment assignments throughout the trial. An unblinded vaccine administrator will administer the appropriate vaccine but will not be involved in safety data collection. The Sponsor and laboratory personnel performing the serology testing will also remain blinded to treatment assignments throughout the trial until database lock. 
The code may be broken by the Investigator only in the event of an SAE and if identification of 
the vaccine received could influence the treatment of the SAE. Code-breaking should be limited, as far as possible, to the subject(s) experiencing the SAE.  
The blind can be broken by the Investigator or a sub- investigator (medical doctor only
a), by 
connecting to the IWRS system  as explained in the code-breaking procedures described in the 
Operating Guidelines. Once the emergency has been addressed by the site, the Investigator must notify the Sanofi Pasteur RMO if a subject’s code was broken. All contact attempts with the 
Sponsor prior to unblinding are to be documented in the source documents. 
A request for the code to be broken may be made: 
• by GPV department for reporting to Health authorities in the case of an SAE as described in 
International Conference on Harmonisation ( ICH) E2A. In this case, the code will be broken 
only for the subject(s) in question. The information resulting from code- breaking (i.e., the 
subject’s  vaccine or group assignment) will not be communicated to either the Investigator or 
the immediate team working on the study, except for the GPV representative. 
                                                 
a  according to local regulations  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 47 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 48 of 82 The IEC  / IRB must be notified of the code-breaking. All documentation pertaining to the event 
must be retained in the site’s study records and in the Sanofi Pasteur  files. Any intentional or 
unintentional code-breaking must be reported, documented, and explained, and the name of the 
person who requested it must be provided to the Sponsor. 
6.5 Randomiza tion and Allocation Procedures  
Each 2 - to 9- year-old subject (who signs an assent form, if ≥  7 years old), whose parent / guardian 
signs the ICF, and who meets the inclusion / exclusion criteria will be randomly assigned to 1 of 2 trial treatment groups (Group 1 and Group 2) in a 1:1 ratio, stratified according to age such that 
each group will have approximately 500 children: 250  children 2 to 5 years old and 250 children 6 
to 9 years old . Site staff will connect to the I WRS, enter the identification and security 
information, and confirm a minimal amount of data in response to IWRS prompts. The I WRS will 
then provide the group assignment and have the site staff  confirm it. The full detailed procedures 
for group allocation are de scribed in the Operating Guidelines. If the subject is not eligible to 
participate in the trial, then the information will only be recorded on the subject recruitment log. 
Subject numbers that are assigned by the IW RS will consist of an 8 -digit string (a 3 -digit trial 
center identifier and a 5 -digit subject identifier connected by a “-”). For example, Subject  001-
00001 is the first subject enrolled in center number 1. 
Subject numbers should not be reassigned for any reason. The Research and Development  (R&D) 
Site Quality Operations  Department  at Sanofi Pasteur will hold the randomization codes in a 
secured location.  
6.6 Treatment Compliance  
The following measures will ensure that the vaccine doses administered comply with those planned, 
and that any non- compliance is documented so that it can be accounted for in the data analyses:  
• All vaccinations will be administered by qualified trial personnel  
• The person in charge of product management at the site will maintain accountability records 
of product delivery to the trial site, product inventory at the site, dose(s) given to each subject, and the disposal of unused or wasted doses 
6.7 Concomitant Medications  and Other Therapies  
At the time of enrollment, ongoing medications including other therapies e.g., blood products, should be recorded in the source document as well as new medications prescribed for new medical conditions / AEs during trial participation.  
Documentation in the CRF of concomitant medication will be limited to specific categories of 
medication of interest beginning on the day of vaccination. This may include medication s of 
interest that were started prior to the day of  vaccination . 
Reportable medications  (see list under Categories 1, 2, and 3 below) will be collected in the CRF 
from the day of vaccination to the end of the solicited and unsolicited follow-up period (e.g., 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 48 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 49 of 82 30 day safety follow-up) as they may impact the response to the vaccination and impact the 
consistency of the information collected on concomitant medications at any vaccination. 
The “reportable” medications are distributed according to 3 categories. These are:  
• Category 1 antipyretics, analgesics, non-s teroidal anti -inflammatory drugs (NSAIDs), 
corticosteroids, and other immune modulators.  
Note: inhaled and topical steroids should not be captured. 
• Category 2: Reportable medications used to define the P er-Protocol Analysis S et (PPAS). For 
example:  
• Influenza and other non- study vaccines: influenza vaccine in the 2 weeks preceding the 
trial vaccination up to the subject’s termination from the trial and any other vaccines 
(other than the study vaccine) in the 4 weeks preceding the trial vaccination up to the 
subject’s termination from the trial. 
• Immune globulins, blood or blood-derived products: used in the 3 months preceding the 
first blood draw and up to the last blood draw 
• Immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy: used 
in the 6 months preceding the trial vaccination and the 4 weeks following the trial vaccination 
• Category 3: Oral or injectable antibiotics , which may interfere with bioassays used for 
antibody testing when taken before a blood draw. 
• The period of collection should be within 3 days before the first blood draw and up to the 
last scheduled blood draw. 
Note: Inhaled and topical antibiotics (drops, creams, or ointments) should not be captured. 
The information reported in the CRF for each reported medication wi ll be limited to:  
• Trade name 
• Given as treatment or as prophylaxis 
• Medication category  
• Start and stop dates  
Dosage and administration route will not be recorded. Homeopathic medication will not be 
recorded.  Topical treatment will not be recorded. 
The fact that a medication was given in response to an AE will be captured in the “Action Taken” 
column of the AE only. No details will be recorded in the concomitant medication module of the CRF unless  the medication received belongs to one of the prelisted categor ies. Medications will 
not be coded. 
7 Management of Samples  
Blood samples for the assessment of antibody respo nses will be collected at Visit s 1 and 2. See 
the Table of Study Procedures  and Section 5.1.3 for details of the sampling schedule. 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 49 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 50 of 82 7.1 Sample Collection  
At Visits 1 and 2, 5 mL of blood will be collected in tubes provided by or recommended by the 
Sponsor. Immediately prior to the blood draw, the staff member performing the procedure will 
verify the subject’s identity; will verify  the assigned subject ’s number on the pre- printed label that 
contains that subject’s number and the sampling stage; and will attach the label to the tube. Blood is to be taken from the limb opposite to the one that will be used for vaccination. 
7.2 Sample Preparation  
Detailed instructions on how to prepare blood samples for assessment of antibody response are contained in the Operating Guidelines provided to the site. An overview of the procedures is provided here. 
Following the blood draw, the sample tubes are to be left undisturbed, positioned vertically and 
not shaken, for a minimum of 1 hour and a maximum of 24 hours in order to allow the blood to 
clot. Samples can be stored at room temperature for up to  2 hours; beyond 2 hours, they must be 
refrigerated at a temperature of +2°C to +8°C and must be centrifuged within a maximum of 
24 hours. 
The samples are then centrifuged, and the separated serum is transferred to the appropriate 
number of aliquoting tube s. These tubes are pre- labeled with adhesive labels that identify the 
study code, the subject’s number and the sampling stage or visit number. 
The subject’s number and the date of sampling, the number of aliquots obtained, the date and time 
of preparation, and the subject’s consent for future use of his / her samples are to be specified on a 
sample identification list and recorded in the source document. Space is provided on this list for 
comments on the quality of samples. 
7.3 Sample Storage and Shipment  
Durin g storage, serum tubes are to be kept in a freezer whose temperature is set and maintained at 
-20°C or below. The temperature will be monitored and documented on the appropriate form during the entire trial. If it rises above -10°C for any period of time, the Clinical Logistics 
Coordinator must be notified. See the Operating Guidelines for further details. 
Shipments to the laboratories will be made only after appropriate monitoring, and following 
notification of the Clinical Logistics Coordinator. Sera will  be shipped frozen, using dry ice to 
maintain them in a frozen state, in the packaging container provided by the carrier . Again, 
temperatures will be monitored. Shipments must be compliant with the International Air 
Transport Association ( IATA ) 602 regulations. 
Samples will be shipped to Global Clinical Immunology (GCI) at Sanofi Pasteur . The address is 
provided in the Operating Guidelines. 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 50 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 51 of 82 7.4 Future Use of Stored Serum Samples for Research  
Any unused part of the serum samples will be securely stored at the Sa nofi Pasteur  serology 
laboratory (GCI) for at least 5  years after the last license approval in the relevant market areas has 
been obtained for the vaccine being tested. 
The s ubjects’ parents  / guardians will be asked to indicate in the ICF  whether they wil l permit the 
future use of any unused stored serum samples for other tests. If they refuse permission, the 
samples will not be used for any testing other than that directly related to this study. If they agree to this use, they will not be paid for giving permission. (Anonymity of samples will be ensured.) The aim of any possible future research is unknown today, and may not be related to this 
particular study. It may be to improve the knowledge of vaccines or infectious diseases, or to 
improve laboratory m ethods. Genetic tests will never be performed on these samples without 
individual informed consent. 
8 Clinical Supplies  
Sanofi Pasteur will supply the trial sites with protocols, ICFs, CRFs, SAE reporting forms, 
pregnancy reporting forms, diary cards, memory aids, and other trial documents, as well as with the following trial materials:  all study vaccine s, blood collection tubes, cryotubes, cryotube 
storage boxes, cryotube labels, temperature recorders, shipping containers, rulers, digital 
thermometers , and pregnancy testing supplies .  
The means for performing Electronic Data Capture (EDC) will be defined by Sanofi Pasteur . If a 
computer is provided by Sanofi Pasteur , it will be retrieved at the end of the trial.  
The Investigator will supply all vaccination su pplies , phlebotomy, and centrifugation equipment, 
including biohazard and / or safety supplies. The biohazard and safety supplies include needles 
and syringes, examination gloves, laboratory coats, sharps disposal containers, and absorbent countertop paper . The site will ensure that all biohazard wastes are autoclaved and disposed of in 
accordance with local practices. The Investigator will also supply appropriate space in a temperature -monitored refrigerator for the storage of the products and for the blood samples, and 
appropriate space in a temperature -monitored freezer for serum aliquots. 
In the event that additional supplies are required, study staff must contact Sanofi Pasteur , 
indicating the quantity required. Contact information is provided in the Operating Guidelines. They must allow approximately 1 week for an order to be filled and to have the supplies sent to their site.  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 51 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 52 of 82 9 Endpoints and Assessment Methods  
9.1 Primary Endpoints and Assessment Methods  
9.1.1 Immunogenicity  
9.1.1.1 Immunogenicity Endpoint  
The primary endpoint for the evaluation of immunogenicity is: 
• Vaccine seroresponse against meningococcal serogroups A, C, Y, and W measured by serum 
bactericidal assays using human complement (hSBA) assessed at baseline (D0, before vaccination) and 30 days (+14 days) aft er vaccination.  
9.1.1.2 Immunogenicity Assessment Method  
 
 
 
 
 
 
 
 
9.1.2 Sa
fety 
There are no primary objectives for safety.  
9.1.3 Efficacy 
No clinical efficacy data will be obtained in the trial. 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 52 of 83

Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 53 of 82 9.2 Secondary Endpoints and Assessment Methods  
9.2.1 Immunogenicity  
9.2.1.1 Immunogenicity Endpoints  
The secondary endpoints for immunogenicity are: 
• GMTs  against meningococcal s erogroups A, C, Y, and W measured by hSBA before and 
30 days (+14 days) after vaccination  with MenACYW conjugate vaccine or MENVEO® 
• Vaccine seroresponse against meningococcal serogroups A, C, Y, and W measured by hSBA 
before and 30 da ys (+14 days) after vaccination  with MenACYW conjugate vaccine or 
MENVEO® 
9.2.1.2 Immunogenicity Assessment Method  
The immunogenicity hSBA assessment method for the secondary endpoints is the same as that 
presented in  Section 9.1.1.2. 
9.2.2 Safety 
There are no secondary objectives for safety.  
9.2.3 Efficacy 
No clinical efficacy data will be obtained in the trial. 
9.3 Observational Endpoints and Assessment Methods  
9.3.1 Immunogenicity  
9.3.1.1 Immunogenicity  Endpoints  
The observational endpoints for immunogenicity are: 
1) Antibody titers against meningococcal serogroups A, C,Y, and W measured by hSBA before 
and 30 days after vaccination with MenACYW conjugate vaccine or MENVEO® 
2) Antibody titers against meningococcal serogroups A, C, Y, and W measured by rSBA before 
and 30 days after vaccination with MenACYW conjugate vaccine or MENVEO® in a subset 
of subjects 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 53 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 54 of 82 9.3.1.2 Immunogenicity Assessment Methods  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.3.2 Sa
fety 
9.3.2.1 Safety Definitions  
The following definitions are taken from the ICH E2A Guideline for Clinical Safety Data 
Management: Definitions and Standards for Expedited Reporting. 
Adverse Event (AE):  
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.  
Therefore an AE may be:  
• A new illness  
• The worsening of a concomitant illness 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 54 of 83

Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 55 of 82 • An effect of the vaccination, including the comparator 
• A combination of the above 
All AEs include serious and non- serious AEs. 
Surgical procedures are not AE s; they are the action taken to treat a medical condition. It is the 
condition leading to the action taken that is the AE  (if it occurs during the trial period).  
Pre-existing medical conditions are not to be reported as AEs. However, if a pre- existing 
condition worsens in frequency or intensity, or if in the assessment of the treating physician there 
is a change in its clinical significance, this change should be reported as an AE (exacerbation). This applies equally to recurring episodes of pre-existing conditions (e.g., asthma) if the frequency or intensity increases post-vaccination. 
Serious Adverse Event (SAE):  
Serious  and severe are not synonymous. The term severe is often used to describe the intensity of 
a specific event as corresponding to Grade  3. This is not the same as seriou s which is based on 
patient / event outcome or action criteria usually associated with events that pose a threat to a 
patient’s life or functioning. Seriousness, not severity, serves as a guide for defining regulatory reporting obligations. 
An SAE is any untoward medical occurrence that at any dose  
• Results in death  
• Is life -threateninga 
• Requires inpatient hospitalization or prolongation of existing hospitalizationb 
• Results in persistent or significant disability  / incapacityc 
• Is a congenital anomaly  / birth  defect  
• Is an important medical eventd 
Adverse Reaction:  
All noxious and unintended responses to a medicinal product related to any dose should be 
considered adverse reactions (AR) . 
                                                 
a  The term “life -threatening” refers to an event in which the subject was at risk of death at the time of the event; it does not refer 
to an event which hypothetically might have caused death if it were more severe.  
b  All medical events leading to hospitalizations will be recorded and reported as SAEs , with the exception of: hospital ization 
planned before inclusion into the study or out -patient treatment with no hospitalization.  
c  “Persistent or significant disability or incapacity” means that there is a substantial disruption of a person’s ability to carry out 
normal life functions . 
d  Medical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate in other situations, 
such as important medical events that may not be immediately life -threatening or result in death or hospitalization but may  
jeopardize the health of the subject or may require intervention to prevent one of the other outcomes listed in the definition above. These should also usually be considered serious. Examples of such events include allergic bronchospasm requiring 
intensiv e treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient 
hospitalization, or the development of drug dependency or drug abuse, GBS, new onset  diabetes, or autoimmune disease
. 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 55 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 56 of 82 (The phrase “responses to a medicinal product” means that a causal relatio nship between a 
medicinal product and an AE  is at least a reasonable possibility)  
Unexpected Adverse Reaction (UAR):  
An unexpected adverse reaction is an AR , the nature or severity of which is not consistent with 
the applicable product information (e.g., Investigator’s Brochure for an unapproved 
investigational medicinal product).  
The following additional definitions are used by Sanofi Pasteur: 
Solicited Reaction:  
A solicited reaction is an event that is prelisted  in the CRF. The assessment of these AEs post-
vaccination is mandatory. A solicited reaction is defined by a combination of: 
• Symptom and 
• Onset post- vaccination  
Examples of solicited reactions include  injection site pain between D0 and D07 post-vaccination 
or headache between D0 and D 07. 
A solicited  reaction is therefore an AR observed and reported under the conditions ( symptom and 
onset) prelisted (i.e., solicited) in the CRF  and considered as related to vaccination . 
Unsolicited AE  / AR:  
An unsolicited AE is an observed AE that does not fulfill the conditions prelisted in the CRF in 
terms of diagnosis and / or onset post-vaccination, i.e., excluding solicited reactions, e.g., if 
headache between D0 and D07 is a solicited reaction  (i.e., prelisted in the CRF), then a headache 
starting on D 07 is a solicited reaction , whereas headache starting on D 08 post- vaccination is an 
unsolicited AE. 
An unsolicited non-serious AE is an unsolicited AE excluding SAEs. 
Injection Site Reaction:  
An injection site reactiona is an AR at and around the injection site. Injec tion site reactions are 
commonly inflammatory reactions.  Systemic AE:  
Systemic AEs are all AEs that are not injection site reactions. They therefore include systemic 
manifestations such as headache, fever, as well as localized or topical manifestations th at are not 
associated with the vaccination site, e.g., erythema that is localized but that is not at the injection 
site. 
                                                 
a  All injection site AEs are  considered to be related to vaccination  and are therefore all injection site reactions . 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 56 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 57 of 82  
 
 
Medica
lly-Attended Adverse Event (MAAE)  
An MAAE is defined, for the purpose of this study, as a new onset of a condition that prompts the 
subject or subject’s parent/guardian to seek unplanned medical advice at a physician’s office or Emergency Department. This definition excludes pre- planned medical office visits for routine 
pediatric check -ups or follow-up visits of chronic conditions with an onset prior to entry in the 
study. Physician contact made over the phone or by email will be considered a physician office visit for the purpose of MAAE collection. The outcome of the physician contact (whether it results in a prescription or not) will not be considered as a basis for reporting the event as an MAAE and all contacts should  be reported. Sufficient data should be collected for the event to 
allow an assessment of the causality and diagnosis, if possible.  
9.3.2.2 Safety Endpoints  
The observational endpoints for the evaluation of safety are : 
• Occurrence, nature (Medical Dictionary for Regulatory Activities [MedDRA] preferred 
term), duration, intensity, and relationship to vaccination of any unsolicited systemic AEs reported in the 30 minutes after vaccination. 
• Occurrence, time of onset, number of days of occurrence, intensity, action taken, and whether 
the reaction led to early termination from the study, of solicited (prelisted in the subject’s diary card and electronic case report form [CRF]) injection site reactions occurring up to 7 days after vaccination . 
• Occurrence, time of onset, number of days of occurrence, intensity, action taken, and whether 
the reaction led to early termination from the study, of solicited (prelisted in the subject’s diary card and CRF) systemic reactions occurring up to 7 days after vaccination. 
• Occurrence, na ture (MedDRA preferred term), time of onset, duration, intensity, action 
taken, relationship to vaccination (for systemic AEs only), and whether the event led to early termination from the study, of unsolicited AEs up to Visit 2 after vaccination.  
• Occurrence, nature (MedDRA preferred term), time of onset, duration, seriousness criteria, 
relationship to vaccination, outcome, and whether the SAE led to early termination from the study, of SAEs  throughout the trial.  
• Occurrence, nature (MedDRA  preferred term), time of onset, duration, seriousness, 
relationship to vaccination, and outcome for MAAEs from Visit 2 to the 6-month follow-up contact. MAAEs will be collected as unsolicited AEs up to Visit 2. 
9.3.2.3 Safety Assessment Methods 
At Visit 2, the Investigator or a delegate will ask the subject ’s parent / guardian about any 
solicited reactions and unsolicited AEs recorded in the diary card, as well as about any other AEs 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 57 of 83

Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 58 of 82 that may have occurred since the previous visit. All relevant data will be transcribed into the CRF 
according to the instructions provided by the Sponsor. 
9.3.2.3.1 Immediate Post-vaccination Surveillance  Period 
Subjects will be kept under observation for 30 minutes after vaccination to ensure their safety . 
The post-vaccination surveillance should be documented in the source document. Any AE that 
occurs during this period will be noted on the source document and recorded in the CRF, as follows: 
• Any unsolicited systemic AE occur ring during the first 30  minutes post- vaccination will 
be recorded on the CRF as immediate unsolicited systemic AE .  
• Solicited and unsolicited injection site reactions and solicited systemic reactions will be 
recorded and analyzed as starting on the day of vaccination.  
• Any SAE occurred during the first 30 minutes post- vacci nation will be reported in the 
same way as any other SAE and to the Sponsor, according to the procedures described in Section 10.  
9.3.2.3.2 Reactogenicity (Solicited Reactions From Day  0 to Day 07 After Vaccination)  
After vaccination , subjects’ parents / guardians will be provided with a safety diary card, a digital 
thermometer, and a flexible ruler, and will be instructed how to use them. T he following items 
will be recorded by the subje cts in the diary card on the day of vaccination and for the next 7 days 
(i.e., D0 to D07) until resolution: 
• Daily temperature, with the route by which it was taken 
• Daily measurement or intensity grade of all other solicited injection site and systemic 
reactions 
• Action taken for each event, if any (e.g., medication) 
The action taken by the parent or guardian to treat any solicited reactions will be classified in the 
CRF using the following scale: 
0: None 
1: Medication (self -medication with an existing prescr iption or over- the-counter medication) 
2: Health care provider contact (no new medication prescribed)  
3:  Health care provider contact and prescription of a new medication (health care provider 
instructed subject to take a new medication, either an over -the-counter medication or one 
requiring a written prescription)  
4: Hospitalization (inpatient) 
Subjects’ parents / guardians will be contacted by telephone 8 days after  vaccination to remind 
them to record all safety information in the diary card.  
If the tim ing of the telephone call should fall on a weekend or a holiday, the call should be made 
on the next business day. If contact is not made on the designated day, study staff will continue 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 58 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 59 of 82 calling until contact is made. Every telephone attempt and its outcome will be documented in the 
source document. 
Table 9.1 a nd Table  9.2 present, respectively, the injection site reactions and systemic reactions 
that are prelisted in the diary cards and CRF, together with the intensity scales.  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 59 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 60 of 82 Table 9.1: Solicited injection site reactions: terminology , definitions , and intensity scales  
CRF term 
(MedDRA lowest 
level term [L LT]) Injection site pain*  Injection site erythema  Injection site swelling  
Diary card term  Pain Redness  Swelling  
Definition  Presence of a redness including the 
approximate point of needle entry Swelling at or near the injection site  
Swelling or edema is  caused by a fluid 
infiltration in tissue or cavity and, depending on the space available for the fluid to disperse, swelling may be either soft 
(typically) or firm (less typical) to touch and 
thus can be best described by looking at the 
size of the swelli ng 
Intensity scale*  
 Grade 1: Easily tolerated  
Grade 2: Sufficiently discomforting to 
interfere with normal behavior or activities  
Grade 3: Incapacitating, unable to perform 
usual activities  Grade 1: > 0 to <  25 mm  
Grade 2: ≥ 25 to <  50 mm  
Grade 3: ≥ 50 mm Grade 1: > 0 to <  25 mm  
Grade 2: ≥ 25 to <  50 mm  
Grade 3: ≥ 50 mm 
*For the subjective reaction of pain, subjects or parents / guardian s will record the intensity level (Grade  1, 2, or 3) in the diary card. For the measu rable reactions of redness and 
swelling, they will record just the size of the reaction, and the classification as Grade  1, 2, or 3 will be assigned at the time of the statistical analysis.  
Sanofi Pasteur  
 
Confidential/Proprietary Information 
                
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 60 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 61 of 82 Table 9.2: Solicited systemic reactions: terminology , definitions , and intensity scales  
CRF term 
(MedDRA LLT) Fever Headache  Malaise Myalgia 
Diary card term  Temperature  Headache  Feeling unwell  Muscle aches and pains  
Definition Elevation of temper ature to ≥ 100.4°F  
(≥ 38.0°C ) Pain or discomfort in the head or 
scalp. Does not include migraine.  General ill feeling.  
Malaise is a generalized feeling of discomfort, illness, or lack of well-
being that can be associated with a 
disease state. It can be accompanied by a sensation of exhaustion or 
inadequate energy to accomplish 
usual activities.  Muscle aches and pains are common and can involve more than one muscle at the same time. Muscle pain can also involve the soft tissues that 
surround muscles. These structures, 
which are often referred to as connective tissues, include ligaments, 
tendons, and fascia (thick bands of 
tendons).  
Does not apply to muscle pain at the injection site which should be reported as injection site pain.  
Intensity scale*  Grade  1: ≥ 100.4°F to ≤  101.1°F or 
≥ 38.0°C to ≤  38.4°C  Grade  1: No interference with activity  Grade 1: No interference with activity  Grade  1: No interference with activity  
 Grade  2: ≥ 101.2°F to ≤  102.0°F or 
≥ 38.5°C to ≤  38.9°C  Grade  2: Some interference with 
activity  Grade 2: Some interference with activity  Grade  2: Some interference with 
activity  
 Grade  3: ≥ 102.1°F or ≥ 39.0°C Grade  3: Significant; prevents daily 
activity  Grade  3: Significant; prevents daily 
activity  Grade  3: Significant; prevents daily 
activity 
*For all reactions but fever, subjects or parents / guardian s will record the intensity level (Grade  1, 2, or 3) in the diary card. For fever, they will record the body temperature, and the 
classification as Grade  1, 2, or 3 will be assigned at the t ime of the statistical analysis . 
 
Sanofi Pasteur  
 
Confidential/Proprietary Information 
                
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 61 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 62 of 82 Important notes for the accurate assessment of temperature:  
Parents / guardians are to measure body temperature once per day, preferably always at the same 
time. The optimal time for measurement is the evening, when body temperature is the highest. 
Temperature is also to be measured at the time of any apparent fever. The observed  daily 
temperature and the route of measurement are to be recorded in the diary card, and the highest 
temperature will be recorded by the site in the CRF. The pr eferred route for this trial is  axillary . 
Pre-vaccination temperature is also systematically collected  by the investigator on the source 
document. Tympanic thermometers must not be used. 
9.3.2.3.3 Unsolicited Non-serious Adverse Events From Day 0 to Day 30 After Vaccination  
In addition to recording solicited reactions, parents / guardians will be instructed to record any 
other medical events that may occur during the 30-day period after vaccination . Space will be 
provided in the diary card for this purpose.  
For each unsolicited non- serious AE, the following information is to be recorded: 
• Start and stop datesa  
• Intensity of the event: 
• For measurable unsolicited non-serious AEs that are part of the list of solicited reactions, 
the size of the AE as well as the temperature for fever will be collected and analyzed 
based on the corresponding scale used for solicited reactions  (see Table 9.1 and 
Table  9.2) 
• Other unsolicited non-serious AEs will be classified according to the following intensity 
scale:  
• Grade  1: No interference with activity  
• Grade  2: Some interference with activity  
• Grade  3: Significant; prevents daily activity  
• Action taken for each AE , if an y (e.g., medication) 
The action taken by the parent or guardian to treat any unsolicited AEs will be classified in the 
CRF using the following scale: 
0: None 1: Medication (self -medication with an existing prescription or over- the-counter medication) 
2: Health care provider contact (no new medication prescribed)  
                                                 
a The stop date of all related AEs will be actively solicited. For other events, the investigator will provide the stop 
date when it becomes available. AEs for which n o stop date was obtained during the course of the trial will be 
considered as ongoing at the end of the trial.  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 62 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 63 of 82 3:  Health care provider contact and prescription of a new medication (health care provider 
instructed subject to take a new medication, either an over -the-counter medication or one 
requiring a written prescription)  
• Whether the AE led to discontinuation 
• Whether the AE was related to vaccination (for unsolicited systemic AEs)  
9.3.2.3.4 Serious Adverse Events 
Information on SAEs will be collected and assessed throughout the trial, from inclusion until 
180 days a fter the last vaccination. The collection of SAEs begins at the time of first dose and 
ends 180 day s (+14 days)  post last dose.  
Any SAE occurring at any time during the trial will be reported by the Investigator through the EDC system  and according to the completion guidelines provided by the Sponsor. All information 
concerning the SAE is to be reported, either as part of the initial reporting or during follow-up reporting if relevant information became available later (e.g., outcome, medical history, resul ts of 
investigations, copy of hospitalization reports) . The Investigator will assess the causal relationship 
between the SAE and the investigational product as either “Not related” or “Related”, as described in  Section 10.4. 
In case a subject experiences convulsion  / seizure episode associated or not with fever, the 
assessment will be performed according to the “Guideline for definition and collection of cases of febrile convulsion”  (37) and this event will be considered an SAE. 
See Section 10 fo r further details on SAE reporting.  
  
 
  
  
  
  
 
 
 
 
 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 63 of 83

Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 64 of 82 9.3.2.3.6 Medically-Attended Adverse Events 
MAAE  informa tion will be collected throughout the study. MAAE s that occur from Visit 1 (D0) 
to Visit 2 (D30[+14days]) will be recorded as unsolicited AEs on the diary card as part of all 
unsolicited AEs collected for this  post -vaccination period. MAAEs that occur from Visit 2 (D30 
[+14 days]) to D180 (+14 days) will be recorded as such in the memory ai d. An MAAE that 
occurs within the study period but meets the definition of an SAE should be reported only on the SAE Repor ting Form, but not on the MAAE page of the CRF. The Investigator will assess the 
causal  relationship between the MAAE  and the investigational or study product as either “Not 
related” or “Related”, as described in  Section 9.3.2.3.7. 
9.3.2.3.7 Assessment of Causality  
The Investigator will assess the causal relationship  between each unsolicited systemic AE and 
vaccination as either not related or related, based on the following definitions
a: 
0: Not related – The AE is clearly  / most probably caused by other etiologies such as 
subject’s underlying condition, therapeutic intervention, or concomitant therapy; or the delay between vaccination and the onset of the AE is incompatible with a causal relationship; or the AE starte d before the  vaccin ation (screening phase , if applicable ) 
1:  Related – There is a “reasonable possibility” that the AE was caused by the vaccination, 
meaning that there is evidence or arguments to suggest a causal relationship  
Note: By convention, all injection site AEs (solicited and unsolicited) and all solicited systemic 
reaction s are considered to be related to vaccination and referred to as reactions, and therefore do 
not require the Investigator’s opinion on relatedness. 
AEs likely to be related to the product, whether serious or not, that persist at the end of the trial 
will be followed up by the Investigator until their complete disappearance or the stabilization of the subject’s condition. The Investigator will inform the Sponsor of the date of final disappearance of  the event. 
9.3.3 Efficacy 
No clinical efficacy data will be obtained in the trial.  
10 Reporting of Serious Adverse Events   
In order to comply with current regulations on SAE reporting to health authorities, the Investigator must document all SAEs regardless of cau sal relationship, and notify the Sponsor and 
the Clinical Research Associate ( CRA) within the notification timelines stated in the following 
sections. The Investigator will give access and provide the Sponsor and the CRA with all 
                                                 
a  ICH Guidelines, Clinical Safety Data Management E2A  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 64 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 65 of 82 necessary information to allow the Sponsor to conduct a detailed analysis of the safety of the 
investigational product(s). It is the responsibility of the Investigator to request all necessary 
documentation (e.g., medical records, discharge summary, autopsy) in order to provide comprehensive safety information. All relevant information must then be transcribed into the electronic Serious Adverse Event ( eSAE ) Form.  
10.1 Initial Reporting by the Investigator  
SAEs occurring during a subject’s participation in the trial or experiment must be reported within 24 hours to the Sponsor’s GPV Department and to the CRA. Every SAE must be reported, even if the Investigator considers that it is not related to the vaccine. The SAE form must be signed by a 
licensed physician (M.D. or D.O .) for whom the task is listed on the Study Task Delegation and 
Signature List after each update to the Form.  
The Investigator must complete the “eSAE Form” in the EDC application. After validation, an e-
mail alert will automatically be sent to the GPV mailbox, the CRA an d the Clinical Team Leader 
(CTL ). This message will include the country, the study code, the subject number, whether the 
report is initial or a follow -up, the diagnosis and / or symptoms, the seriousness criteria, the 
relationship, if related  and the outco me, if fatal . 
If the EDC system is unavailable, the site must notify the Sponsor using the paper version of the SAE Reporting Form, as follows: 
The Investigator must complete the SAE Reporting Form, check off the “Initial Reporting Form” 
box, and send it to the Sponsor by one of the following means (preferably by fax or e- mail): 
• By fax, to the following number:  
• In PDF format to the following e-mail address, using a method of transmission that includes password protection:  (see the Operating 
Guidelines for directions on how to send a password protected email). 
• By express mail, to the following address: Sanofi Pasteur Inc. 
Reception and Triage – Case Management  
Global PharmacoVigilance Mail Drop: 45D38 Discover y Drive 
Swiftwater, PA 18370 
When the system becomes available, the Investigator must transcribe the information from the paper version of the eSAE Form into the EDC system. 
If there is need for urgent consultation, the Investigator is to contact the RMO . If the RMO cannot 
be reached, the Investigator may  contact the Call Center as described in  Section 5.3.  
10.2 Follow-up Reporting by the Investigator  
The eSAE Form completed initially must be updated within 24 hours after the Investigator has 
become aware of any new relevant information concerning the SAE (e.g., outcome, precise description of medical history, results of the investigation). After validation, an e- mail alert will 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 65 of 83

Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 66 of 82 be sent automatically to the GPV Department and to the CRA. All relevant information must be 
included directly in the eSAE form. Copies of documents (e.g., medical records, discharge 
summary, autopsy) may be requested by the GPV Department.  
The anonymity of the subject must always be respected when forwarding this information. 
10.3 Reporting of SAEs Occurring After a Subject Has Completed the Study  
Any SAE that occurs after a subject has completed the study but that is likely to be related to the product or to the experiment must also be reported as soon as possible. In such a case, the reporting procedure to be followed is identical to that described in Section 10.1. 
10.4 Assessment of Causality  
The causal relationship between the SAE and the product will first be evaluated by the Investigator, using the following definitions: 
0 - Not related : The AE is clearly  / most probably caused by other etiologies such as an 
underlying condition, therapeutic intervention, or concomitant therapy; or the delay between vaccination and the onset of the SAE is incompatible with a causal relationship; or the SAE started before the vaccination  (screening phase, if applicable) . 
1 - Related : There is a “reasonable possibility” that the SAE was caused by the vaccination, 
meaning that there is evidence or arguments to suggest a causal relationship.  
(ICH Guidelines, Clinical Safety Data Management E2A) 
Following this, the Sponsor’s Product Safety Officer (PSO)  will als o assess the causal relationship 
to the product, based on the available information and current medical knowledge. 
The decision to modify or discontinue the trial may be made after mutual agreement between the 
Sponsor and the Investigators. 
10.5 Reporting SAEs to Health Authorities and IECs  / IRBs 
The Sponsor will inform the relevant health authorities of any reportable SAEs according to the local regulatory requirements. Reporting to the health authorities will be according to the Sponsor’s standard operating p rocedures.  
The Sponsor’s , will notify the Investigators in writing of the 
occurrence of any reportable SAEs. The Investigators / Sponsor will be responsible for informing 
the IECs or IRBs that reviewed the trial protocol.  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 66 of 83

Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 67 of 82 11 Data Collection and Management  
11.1 Data Collection and CRF Completion  
Individual safety diary cards, specifically designed for this trial by the Sponsor and provided to 
the study sites, will be given to study participants for the recording of daily safety information as described in  Section 9.3.2.3. These diary cards will include prelisted terms and intensity scales 
(see Table 9.1  and Table  9.2) as well as areas for free text to capture additional safety information 
or other relevant details. P arents or guardians will also be provided with rulers for measuring the 
size of injection site reactions, and with standard digital thermometers for measuring daily 
temperatures. To ensure consistency of reporting, the study sites will instruct parents / guardians 
on how to correctly use these tools. 
The 6 -month follow-up will be done by interviewing subjects either during a visit or over the 
telephone using a questionnaire to capture SAEs and AEs of particular interest, if applicable. A n 
MA will be provided to the subjects (or the subject’s parent / guardian ) at the preceding trial visit 
to help them record information on events occurring between this visit and the 6-month follow-up. Relevant information will be transcribed into the CRF. Any SAEs captured during this 6-month 
follow-up period will be reported and followed-up as per the normal process for reporti ng SAEs.  
The clinical team may decide to replace the memory aid by a diary card if a follow -up visit is 
planned for the subjects. 
At specified intervals, the Investigator or an authorized designee will interview the parents  / 
guardians to collect the infor mation recorded in the diary card, and will attempt to clarify 
anything that is incomplete or unclear. All clinical trial information gathered by the study site will 
be reported electronically by the Investigator or authorized designee using a web-based CR F. 
(Any information that was not documented in the diary card will first be captured in the source document and then reported electronically.) The CRF has been designed specifically for this trial under the responsibility of the Sponsor, using a validated Electronic Records / Electronic Signature-compliant platform (21 CFR Part 11). 
To ensure the correct and consistent completion of the CRFs, the Sponsor or authorized 
representative will provide all necessary tools, instructions, and training to all site staff involved in data entry prior to study start. Additional instructional documents such as training manuals and completion guidelines will be provided to assist with data entry during the course of the trial. 
Upon completion of training, each user requiri ng access to the EDC system will be issued a 
unique username and password. In the event of a change in trial personnel, each newly assigned 
individual will receive a unique username and password; the username and password of a previous user may not be reissued. If any trial personnel leave the study, the Investigator is 
responsible for informing the Sponsor immediately so that their access is deactivated. An audit 
trail will be initiated in the EDC system at the time of the first data entry in order to track all modifications and to ensure database integrity. 
The Investigator is responsible for the timeliness, completeness, and accuracy of the information 
in the CRFs; must provide explanations for all missing information; and must sign the CRF using an e- signature. 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 67 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 68 of 82 11.2 Data Management  
Management of Clinical Data  
Data generated during the trial will be managed following two different processes:  
Clinical data, defined as all data reported in the CRF, and laboratory data will be handled by the 
Sponsor’s Clinical Dat a Management (CDM) platform or authorized representative.  
Data pertaining to SAEs, which are reported by the Investigator on the eSAE Forms or SAE Reporting Forms, will be handled by the Sponsor’s GPV Department.  
During the trial,  clinical data reported in  the CRFs will be integrated into the clinical database 
under the responsibility of the Sanofi Pasteur  CDM platform. Data monitoring at the sites and 
quality control in the form of computerized logic and / or consistency checks will be 
systematically appli ed in order to detect errors or omissions. In addition, data reviews may be 
performed several times by the Sponsor’s staff in the course of the trial. Any questions pertaining to the reported clinical data will be submitted to the investigator for resolution using the EDC system. Each step of this process will be monitored through the implementation of individual passwords to maintain appropriate database access and to ensure database integrity.  
The validation of the immunogenicity data will be performed at the laboratory level following the 
laboratory’s procedures. Information from the laboratory will be checked for consistency before integration into the clinical database.  
After integration of all corrections in the complete set of data, and after the SAE information 
available from CDM and the GPV Department has been reconciled, the database will be released for 
statistical analysis.  
SAE Data Management  
During the trial, data pertaining to SAEs reported on eSAE Forms will be integrated into the 
Sponsor’s c entralized GPV  database.  
Upon receipt of an eSAE Form, the data will be entered into the GPV database after a duplicate 
check. Each SAE case will be assigned a case identification number. Each case will be entered in the GPV database and assessed by the case management platform or its delegate before being reported to the relevant authorities as necessary. Assessment of related cases will be done in collaboration with the PSO and the RMO. Follow-up information concerning a completed case will be entered into the GPV database, and a new version of the case will be created.  
The information pertaining to SAEs in the GPV  database will be reconciled with that in the 
clinical database.  
11.3 Data Review  
A blind review of the data is anticipated through the data review process led by D ata Management 
before database lock.  The safety of the investigational product will be continuously monitored by 
the Sponsor. Periodic safety data review will be performed by the Sponsor’s SMT. For all periodic safety reviews, blinded safety  data will be provided to the Sponsor’s SMT. 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 68 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 69 of 82 12 Statistical Methods and Determination of Sample Size  
12.1 Statistical Methods  
Clinical data will be analyzed under the responsibility of the Biostatistics Platform of the Sponsor. 
A statistical analysis plan (SAP) will be written and peer reviewed before any analyses. In accordance with the protocol, the SAP will describe all analyses to be performed under the 
responsibility of the Sponsor and all the conventions to be taken. 
12.1.1 Hypotheses and Statistical Methods for Pri mary Objective  
Thirty days
a after the administration  of MenACYW conjugate vaccine or MENVEO®, the 
percentages of subjects who achieve an hSBA vaccine seroresponseb for meningococcal 
serogroups A, C, Y, and W in Group 1 are non- inferior to the corresponding percentages in 
Group 2. 
Null hypothesis (H 0): p (G1) - p  (G2) ≤ -10% 
Alternative hypothesis (H 1): p (G1) - p  (G2) > -10% 
where p (G1) and p  (G2) are the percentages of subjects who achieve an hSBA  vaccine seroresponse 
in Group 1 and Group 2, respectively. Each of the serogroups A, C, Y, and W will be tested 
separately. If the lower limit of the 2 -sided 95% confidence interval (CI) of the difference 
between the 2  proportions is > -10%, the inferiority assumption will be rejected. 
For the 4 non- inferiority h ypotheses using the seroresponse rates, the CI of the difference in 
proportions will be computed using the Wilson Score method without continuity correction  (44). The overall non- inferiority of this objective will be demonstrated if all 4 individual null 
hypotheses are rejected.  
12.1.2 Hypotheses and Statistical Methods for Secondary Objectives 
No hypotheses will be tested. Descriptive statistics will be presented.  
12.1.2.1 Secondary Objective 1  
Thirty days
a after the  administration of MenACYW conjugate vaccine or MENVEO®, the hSBA 
geometric mean titer ratio (GMTR) between Group 1 and Group 2 will be calcula ted and 95% CI 
will be provided. 
                                                 
a  D30 (+14 days) 
b  The hSBA vaccine seroresponse for serogroups A, C, Y, and W is define d as: 
• For a subject with a pre- vaccination titer < 1:8 , the post -vaccination titer must be ≥ 1:16. 
• For a subject with a pre- vaccination titer ≥ 1:8, the post -vaccination titer must be at least 4 -fold greater 
than the pre -vaccination titer.  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 69 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 70 of 82 12.1.2.2 Secondary Objective 2  
Thirty daysa after the administration of MenACYW conjugate vaccine or MENVEO®, the hSBA 
GMTR between Group 1a and Group 2a, and between Group 1b and Group 2b will be calculated 
and 95% CI will be provided, respectively . 
12.1.2.3 Secondary Objective 3  
Thirty daysa after the  administration of MenACYW conjugate vaccine or MENVEO®, the 
differen ce of hSBA vaccine seroresponseb rates between Group 1a and Group 2a, and between 
Group 1b and Group 2b will be calcula ted a nd 95% CI will be provided, respectively. 
12.1.3 Statistical Methods for Obs ervational Objectives 
No hypotheses will be tested. Descriptive statistics will be presented.  
12.1.3.1 Immunogenicity  
Descriptive statistics will be provided for the antibody titers against meningococcal serogroups contained in MenACYW conjugate vaccine and MENVEO
®. 
In general, categorical variables will be summarized and presented by frequency counts, percentages, and CIs. The 95% CIs of point estimates will be calculated using the normal approximation for quantitative data and the exact binomial distribution (Clopper- Pearson method) 
for percentages. For GMTs, 95% CIs of point estimates will be calculated using normal approximation assuming they are log- normally distributed.  
Reverse cumulative dist ribution curve (RCDC) figures will be provided for the antibody titers 
against meningococcal serogroups contained in MenACYW conj ugate vaccine and MENVEO
® 
treatment groups. 
Descriptive analyses on A, C, Y, and W serogroups on D0 and D30 (+14 days) using hS BA will 
include but not be limited to: 
• GMT  and 95% CI in Group 1, Group 2, Group 1a, Group 1b, Group 2a, and Group 2b 
• Titer distribution and RCDC  
• Percentage of subjects with titer ≥ 1:4 and ≥ 1:8 and 95% CI in Group 1, Group 2, 
Group 1a, Group 1b, Group 2a, and Group 2b 
• Percentage of subjects with titer ≥  4-fold rise from pre -vaccination to post-vaccination, 
and 95% CI in Group 1, Group 2, Group 1a, Group 1b, Group 2a, and Group 2b 
                                                 
a  D30 (+14 days) 
b  The hSBA vaccine seroresponse for serogroups A, C, Y, and W is defined as : 
• For a subject with a pre- vaccination titer < 1:8, the post -vaccination titer must be ≥ 1:16. 
• For a subject with a pre- vaccination titer ≥ 1:8, the post -vaccination titer must be at least 4 -fold greater 
than the pre -vaccination tit er. 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 70 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 71 of 82 • Percentage of subjects with hSBA vaccine seroresponsea and 95% CI in Group 1, Group 2, 
Group 1a, Group 1b, Group 2a, and Group 2b 
Descriptive analyses on A, C, Y, and W serogroups on D0 and D30 (+14 days) using rSBA will 
include but not be limited to: 
• GMT  and 95% CI in a subset of 200 subjects in Group 1 and Group 2, and in a subs et of 
100 subjects in Group 1a, Group 1b, Group 2a, and Group 2b 
• Titer distribution and RCDC s 
• Percentage of subjects with titer ≥ 1:8 and ≥ 1:128 and 95% CI in a subset of 200 subjects 
in Group 1 and Group 2, and in a subset of 100 subjects in Group 1a, Group 1b, Group 2a, 
and Group 2b 
• Percentage of subjects with  titer ≥  4-fold rise from pre -vaccination to post -vaccination and 
95% CI in a subset of 200 subjects in Group 1 and Group 2, and in a subset of 100 subjects in Group 1a, Group 1b, Group 2a, and Group 2b 
• Percentage of subjects with rSBA v accine seroresponseb and 95% CI in a subset of 
200 subjects in Group 1 and Group 2, and in a subset of 100 subjects in Group 1a, Group 1b, Group 2a, and Group 2b 
12.1.3.2 Safety 
For this trial, the safety data will be assessed by applying descriptive statistical methods, 
supplemented by the calculation of CIs to aid interpretati on. The exact binomial distribution 
(Clopper-Pearson method) for proportions will be used in the calculation of the 95% CIs of events.  
The frequency and percentage of subjects who had solicited injection site and systemic reactions and their 95% CIs will b e provided. These events will be tabulated by type of reactions and 
intensity for Group 1 and Group 2. These events will also be summarized by other categories 
specified in the endpoints (e.g., time of onset, number of days of occurrence, action taken). 
Unsolicited AEs will be collected, coded, and summarized by MedDRA system organ class and 
preferred term. For each unsolicited AE, the number of subjects with at least one instance of that 
event will be reported. Unsolicited AEs will also be tabulated by intensity and relatedness of study vaccine and by other categories specified in the endpoints. 
Immediate reactions, SAEs, and any event that leads to subject withdrawal from the study will be 
tabulated separately . 
                                                 
a hSBA vaccine seroresponse for serogroups A, C, Y, and W is defined as:  
• For a subject with a pre- vaccination titer < 1:8, the post -vaccination titer must be ≥ 1:16. 
• For a subject with a pre- vaccination titer ≥ 1:8, the post -vaccination titer must be a t least 4 -fold greater than 
the pre -vaccination titer.  
b  rSBA vaccine seroresponse is defined as a post -vaccination titer ≥  1:32 for subjects with pre -vaccination rSBA 
titer < 1:8, or a post -vaccination titer ≥  4 times the pre -vaccination titer for subjec ts with pre -vaccination rSBA 
titer ≥ 1:8.  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 71 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 72 of 82 12.2 Analysis Sets  
Three analysis sets will be used: the Full Analysis Set (FAS), the Per-Protocol Analysis Set 
(PPAS), and the Safety Analysis Set (SafAS) . 
12.2.1 Full Analysis Set  
The FAS is defined as the subset of  subjects who received at least one dose of the study vaccine 
and had a valid post-vaccination serology result. All subjects will be analyzed according to the 
treatment group to which they were randomized. 
12.2.2 Safety Analysis Set 
The Safety Analysis Set (SafAS) is defined as those subjects who have received study vaccinea 
and have any safety data availab le. All subjects will have their safety analyzed according to the 
vaccine they actually received . 
Safety data recorded for a vaccine received out of the protocol design will be excluded from the 
analysis (and listed separately).  
12.2.3 Per-Protocol Analysis Set  
The Per-Protocol Analysis S et (PPAS) is a subset of the FAS. The subjects presenting with at 
least one of the following relevant protocol deviations will be excluded from the PP AS: 
• Subject did not meet all protocol-specified inclusion criteria or met at lea st one of the 
protocol- specified exclusion criteria  
• Subject did not receive vaccine  
• Subject received a vaccine other than the one that he / she was randomized to receive  
• Preparation and / or administration of vaccine was not done as per-protocol 
• Subject d id not receive vaccine in the proper time window  
• Subject did not provide the post-dose serology sample in the proper time window or a post-
dose serology sample was not drawn . The time window will be defined as D30 to D44 
(D30  +14 days) post-vaccination. 
• Subject received a protocol -prohibited  Category 2 or Category 3 therapy / medication  / 
vaccine  
• Subject’s serology sample did not produce a valid test result 
• Subject had other protocol violations that affected the subject’s immune response, as 
determined by the clinical team before locking the database.  
                                                 
a  For which safety data are scheduled to be collected  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 72 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 73 of 82 12.2.4 Populations Used in Analyses  
All immunogenicity analyses will be performed on the PPAS. Additional immunogenicity 
analyses will be performed for exploratory purposes on the FAS. In the FAS, subjects will be analyzed by the vaccine group to which they were randomized. 
All safety analyses will be performed on the SafAS. Subjects will be analyzed according to the vaccine they actually received.  
12.3 Handling of Missing Data and Outliers  
12.3.1 Safety 
No replacement will be do ne. 
12.3.2 Immunogenicity  
Missing data will not be imputed. No test or search for outliers will be performed.  
In order to appropriately manage extreme values (undetectable responses < LLOQ and ≥ upper limit of quantitation [ULOQ]), the following computational rule is applied to the values provided in the clinical database for each blood sample drawn for analysis p urposes: 
• If a value is < LLOQ, then use the computed value LLOQ/2  
• If a value is between ≥ LLOQ and < ULOQ, then use the value 
• If a value is ≥ ULOQ, then use the computed value ULOQ 
The derived endpoint of fold- rise is computed as follows for extreme values, to minimize the 
numerator and maximizes the denominator: 
• If the baseline computed value is < LLOQ and the post-baseline computed value is < LLOQ 
then the fold- rise is 1  
• If the baseline computed value is ≥ LLOQ and the post-baseline computed value is ≥ LL OQ 
then the fold- rise is post- baseline computed value / baseline computed valu e 
• If the baseline computed value is ≥ LLOQ and the post-baseline computed value is < LLOQ then the fold- rise is (LLOQ/2) / baseline computed value  
• If the baseline computed value is < LLOQ and the post-baseline computed value is ≥ LLOQ then the fold- rise is post- baseline computed value /LLOQ  
12.3.3 Efficacy 
Not applicable. 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 73 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 74 of 82 12.4 Interim / Preliminary  Analysis 
Due to the possibility of delayed availability of the immunogenicity data generated us ing rSBA in 
a subset of subjects,  and in order to not delay the analysis of safety data and available hSBA 
immunogenicity data, the analysis on rSBA immunogenicity data will be done separately when all 
rSBA testing has been completed. No statistical adjust ment will be applie d as there will be no 
repeat analysis of the same parameter  and because the rSBA immunogenicity analysis is 
descriptive in nature . 
12.5 Determination of Sample Size and Power Calculation  
 
  
  
 
 
 
   
   
     
     
     
     
     
 
 
13 Ethical and Legal Issues and Investigator / Sponsor Responsibilities  
13.1 Ethical Conduct of the Trial / Good Clinical Practice  
The conduct of this trial will be consistent with the standards established by the Declaration of 
Helsinki and compliant with the ICH guidelines for good clinical practice (GCP) as well as with all local and / or national regulations and directives. 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 74 of 83

Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 75 of 82 13.2 Source Data and Source Documents 
“Source data” are the data contained in source documents. Source documents are original 
documents or certified copies, and include, but are not limited to, diary cards, medical and hospital records, screening logs, informed consent / assent forms, telephone contact logs, and 
worksheets. The purpose of trial source documents is to document the existence of subjects and to substantiate the integrity of the trial data collected. Inv estigators must maintain source documents 
so that they are accurate, complete, legible, and up to date. 
For missing or discrepant data on a diary card, the study coordinator will obtain verbal clarification  
from the subject, enter the response into the “in vestigator’s comment” page of the diary card, and 
transfer the information to the CRF. The subject pre -screening  log should list all individuals contacted by the Investigators to 
participate in the trial, regardless of the outcome.  
The Investigator must pr int
a any electronic records on an ongoing basis, sign and date them 
immediately after creation, and keep the printouts on file as source documents that can be verified 
by the Sponsor or an inspector against the electronic records. Any later changes of an e lectronic 
record require the record to be re -printed, dated (with an indication of the date of change), and 
signed. Such records must also be kept together with the original printed copy. 
13.3 Confidentiality of Data and Access to Subject Records  
Prior to initi ation of the trial, the Investigator will sign a fully executed confidentiality agreement 
with Sanofi Pasteur . 
Sanofi Pasteur personnel (or designates), the IECs / IRBs, and regulatory agencies, including the 
FDA, require direct access to all study records, and will treat these documents in a confidential manner. 
In the event a subject’s medical records are not at the investigational site, it is the responsibility of 
the investigator to obtain those records if needed. 
13.4 Monitoring, Auditing, and Archiving  
13.4.1 Monitoring  
Before the start of the trial (i.e., before the inclusion of the first subject in the first center),  the 
Investigators and the Sponsor’s staff or a representative will meet at the site -initiation visit to 
discuss the trial protocol and the detaile d trial procedures. Emphasis will be placed on inclusion 
and exclusion criteria, visit timing, safety procedures, informed consent procedures, SAE reporting procedures, CRF completion, and the handling of samples and products. The Sponsor’s 
                                                 
a  Unless the electronic medical records are managed by validated computerized systems that are compliant with US 
21 CFR Part 11, in which case they are accept able on their own.  
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 75 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 76 of 82 staff or a representative will ensure and document that all material to be used during the trial has 
been received at the site; and that the study investigator team and local Sponsor /delegate  staff 
have been properly informed about the trial, GCP and regulatory requirements, and the Sponsor’s 
procedures. Specific training sessions for the study investigator team and the CRAs on these topics may be performed as necessary, and should be documented. 
The following instruction manuals will be provided: the CRF Completion Guide lines  for entering 
data into the CRF, and the Operating Guidelines for detailed trial procedures such as the product 
management and sample-handling procedures. 
After the start of the trial, the Sponsor’s staff or a representative will be in regular contact with the 
investigational team through telephone calls and regular follow-up visits. The Investigator or delegate must be available for these visits, and must allow the Sponsor /delegate staff direct access 
to subject medical files and CRFs. During these vi sits, the Sponsor/delegate staff will:  
• Evaluate the quality of the trial progress (adherence to protocol and any study- specific 
guidelines, quality of data collection and document completion, signature of consent forms, occurrence of SAEs, sample and product management, cold -chain monitoring, archiving) 
• Source-verify completed CRFs and any corresponding answered queries 
• Determine the number of complete or ongoing issues identified at monitoring visits (e.g., protocol deviations , SAEs) . Any identified problems will be discussed with the Investigator, 
and corrective or preventive actions will be determined, as appropriate. 
• After all protocol procedures have been completed and the data have been entered into the CRF, the Investigator must still be available to answer any queries forwarded by the Sponsor. 
All data -related queries must be completed prior to database lock.  
At the end of the trial, a close-out visit will be performed to ensure that: 
• The center has all the documents necessary for archiving  
• All sample s have been shipped to the appropriate laboratories 
• All unused materials and products have been either destroyed or returned to the Sponsor 
13.4.2 Audits and Inspections  
A quality assurance audit may be performed at any time by the Sponsor’s Clinical and Medical 
Quality Operations department (C&MQO)  or by independent auditors to verify that the trial has 
been conducted according to the protocol, GCP and ICH requirements, and other applicable regulations. An inspection may be conducted by regulatory authorities. The Investigator must allow direct access to trial documents during these inspections and audits.  
13.4.3 Archiving  
The Investigator must keep all trial documents after the completion or discontinuation of the trial, 
whatever the nature of the investigational center (private practice, hospital, or institution), for as 
long as required by applicable laws and regulations. In the absence of any applicable laws or regulations, trial documents will be kept at a minimum for the duration indicated on the Clinical Trial Agre ement (CTA) . In no event, should study personnel destroy or permit the destruction of 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 76 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 77 of 82 any trial documents  upon less than 90 days advance written notification to the Sponsor. In 
addition, trial documents should continue to be stored, at Sponsor's sole expense, in the event that 
the Sponsor requests in writing that such storage continues for a period of time that exceeds that required by any applicable law or regulation or the CTA . The Investigator will inform Sanofi 
Pasteur of any address change or if they will no longer be able to house the trial documents. 
Archived data may be held on electronic records, provided that a back-up exists and that a hard 
copy can be obtained if required. The protocol, documentation, approvals, and all other documents related to  the trial, including certificates attesting that satisfactory audit and inspection 
procedures have been carried out, will be kept by the Sponsor in the Trial Master File (TMF). Data on AEs are included in the TMF. All data and documents will be made avail able if requested 
by relevant authorities.  
13.5 Financial Contract and Insurance Coverage  
A Clinical Trial Agreement will be signed by all the parties involved in the trial’s performance, if relevant. The Sponsor has an insurance policy to cover any liabilities that may arise from use of the product and / or the study protocol. 
13.6 Stipends for Participation  
The subject’s parent / guardian may be provided with a stipend according to local practice to 
compensate for the time and travel required for study visits and procedures. 
13.7 Publication Policy  
Data derived from this trial are the exclusive property of Sanofi Pasteur . Any publication or 
presentation related to the trial must be submitted to Sanofi Pasteur  for review before submission 
of the manuscript. After publication of the results of the trial, any participating center may publish or otherwise use its own data provided that any publication of data from the trial gives recognition to the trial group. In addition, Sanofi Pasteur  shall be offered an association with all such 
publications, it being understood that Sanofi Pasteur  is entitled to refuse the association.  
Sanofi Pasteur must have the opportunity to review all proposed abstracts, manuscripts, or 
presentations regarding this trial at least 90  days prior to submission for publication / presentation. 
Any information identified by Sanofi Pasteur  as confidential must be deleted prior to submission, 
it being understood that the results of this trial are not to be considered confidential.  
Sanofi Pasteur’s review can  be expedited to meet publication guidelines. 
 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 77 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 78 of 82 14 References List 
 
1 Granoff DM, Harrison LH, Pelton S. Meningococcal vaccines. In: Plotkin SA, Orenstein 
WA, Offit PA, editors. Vaccines . 6th ed. Philadelphia (PA):Saunders (Elsevier);2013:388-
418. 
2 Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. 
Vaccine. 2009;27(Suppl 2):B51-63. 
3 Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, et al. Description and 
nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis 2013;19(4):566 -73 
4 Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr 
Infect Dis J. 2004;23(12 Supp):S274-9. 
5 Kvalsvig AJ, Unsworth DJ. The immunopathogenesis of meningococcal disease. J Clin 
Pathol. 2003;56(6):417- 22. 
6 Sidikou F, Djibo S, Taha MK, Alonso JM, Djibo A, Kairo KK , et al. Polymerase chain 
reaction assay and bacterial meningitis surveillance in remote areas, Niger. Emerg Infect 
Dis. 2003;9(11):1486-8. 
7 World Health Organization. Meningococcal disease, serogroup W135 (update). WER. 
2001;76(28):213-4. 
8 Ibarz -Pavon AB, Gabastou J-M. Improving surveillance and characterization of 
meningococcal disease in Latin America and the Caribbean region: a collaborative research 
program for strengthening regional surveillance network based on laboratory evidence of N. meningitidis. Final Report 2010-2013. Available at URL: https://partners.sanofi.com/global/menactra/Documents/PAHO%20SIRE VA%202%20Meni
ngococcal%20Surveillance%20Final%20Report.pdf.Accessed 11 December 2013. 
9 Ceyhan M, Yildirim I, Balmer P, Borrow R, Dikici B, Turgut M, et al. A prospective study 
of eti ology of childhood acute bacterial meningitis, Turkey. Emerg Infect Dis. 
2008;14(7):1089-96. 
10 Kilic A, Urwin R, Li H, Saracli MA, Stratton CW, Tang YW. Clonal spread of serogroup 
W135 meningococcal disease in Turkey. J Clin Microbiol. 2006;44(1)222-4. 
11 Shao Z, Zhou H, Gao Y, Ren H, Xu L, Kan B. Neisseria meningitidis serogroup W135, 
China. Emerg Infect Dis. 2010;16:348-9. 
12 Zhou H, Wei L, Li Xu, et al. Spread of neisseria meningitidis Serogroup W Clone, China. 
Emerg Infect Dis. 2013. 19(9):1496-1499. 
13 Efron AM, Sorhouet C, Salcedo C, Abad R, Regueira M, Vasquez JA. W135 invasive 
meningococcal strains spreading in South America:significant increase in Argentina. J Clin Microbiol. 2009;47(6):1979-80. 
14 Weidlich L, Baethgen LF, Mayer LW, Moraes C, Klein CC, Nunes LS, et al. High 
prevalence of Neisseria meningitidis hypervirulent lineages and emergence of W135:P1.5.2:ST-11 clone in southern brazil. J Infect. 2008;57(4):324 -31. 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 78 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 79 of 82 15 Barroso DE, Rebelo MC. Recognition of the epidemiological significance of Neiserria 
meningitidis capsular serogroup W135 in Rio de Janeiro region, Bra zil. Mem Inst Oswaldo 
Crus. 2007;102(6):773-5. 
16 Boisier P, Nicholas P, Djibo S, Taha MK, Jeanne I, Mainassara HB, et al. Meningococcal 
meningitis: unprecedented incidence of serogroup X -related cases in Niger. Clin Infect Dis 
2007:44(5):657-63. 
17 Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, et al. The 
changing epidemiology of meningococcal disease in the United States, 1992 -1996. J Infect 
Dis 1999;180(6):1894-901. 
18 Canadian Immunization Committee and Public health Agency of Canada. Advice for 
consideration of quadrivalent (A,C,Y,W -135) meningococcal conjugate vaccine, for use by 
provinces and territories. CCDR. 2010;36(S2):1- 35. 
19 Broker M, Jacobsson S, Kuusi M, Pace D, Simoes MJ, Skoczynska A, et al. Meningococcal 
serogroup Y emergence in Europe: update 2011. Hum Vaccin Immunother. 2012;8(12):1907-11. 
20 Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, et al. Changes in 
Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184-91. 
21 National Foundation for Infectious Diseases. Addressing the challenges of serogroup B 
meningococcal disease outbreaks on campuses: A report by the National Foundation for Infectious Diseases. May 2014. Available online: http://www.nfid.org/meningococcal-b. Accessed 23 February 2015. 
22 Centers for Disease Control and Prevention. Interim guidance for control of serogroup B 
meningococcal disease outbreaks in organizational settings. Available online: http://www.cdc.gov/meningococcal/downloads/interim-guidance.pdf. Accessed 29 June 2015. 
23 European Centre for Disease Prevention and  Control. Surveillance of invasive bacterial 
diseases in Europe 2008/2009. Stockholm: ECDC; 2011. 
24 Public Health England. Increase in endemic meningococcal group W (MenW) ST-11 
comp lex associated with severe invasive disease in England and Wales. Health Protection 
Weekly Report. Vol 8 No 41 Published on: 24 October 2014. Available online: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/367588/hpr4114.pdf. Accessed 29 June 2015. 
25 Törös B, Thulin Hedberg S, Jacobsson S, Fredlund H, Olcén P, Mölling P. Surveillance of 
invasive Neisseria meningitidis with a serogroup Y update, Sweden 2010 to 2012. Euro Surveill. 2014;19(42):pii=20940. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20940. Accessed 11 June 2015. 
26 Thulin Hedberg S, Törös B, Fredlund H, Olcén P, Mölling P. Genetic characterisation of the 
emerging invasive Neisseria meningitidis serogroup Y in Sweden, 2000 to 2010. Euro Surveill. 2011;16(23):pii=19885. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19885. Accessed 11 June 2015 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 79 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 80 of 82 27 The European Meningococcal Disease Society (EMGM). 11th EMGM Meeting, 18 -20 May 
2011. Ljubljana Slovenia. Poster P035, 037-040. 
28 Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs) 
Report: Neisseria meningitidis, 2013. Available online: http://www.cdc.gov/abcs/reports -
findings/survreports/mening13.html. Accessed 22 September 2015. 
29 Centers for Disease Control and Prevention. Update: Guillain -Barré syndrome among 
recipients of Menactra meningococcal conjugate vaccine --Unite d States, June 2005-
September 2006. MMWR Morb Mortal Wkly Rep. 2006; 55(41):1120-4. 
30 Velentgas P, Amato AA, Bohn RL, Chan KA, Cochrane T, Funch DP, et al. Risk of 
Guillain -Barre syn drome after meningococcal conjugate vaccination. Pharmacoepidemiol 
Drug Saf. 2012;21(12):1350-8. 
31 National Research Council. Diphtheria toxoid, tetanus toxoid, and acellular pertuss is 
containing vaccines. In: Stratton K, Ford A, Rusch E, Clayton EW, editors. Adverse effects of vaccines: evidence and causality. Washington (DC): The National Academies Press; 2012. p. 557-8. 
32 Stratton KR, Howe CJ, Johnston RB Jr., editors. Adverse events associated with childhood 
vaccines; evidence bearing on causality. Washington (DC): National Academy Press; 1994. p. 67-117. 
33 Centers for Disease Control and Prevention. General recommendations on 
immunization:recommendations of the Advisory Committee on Immunization Practices (ACIP):MMWR. 2011;60(2):1 -60. 
34 Sutherland A, Izurieta H, Ball R, et al. Syncope after vaccination. United States, January 
2005-July 2007. MMWR 2008;57(17):457-60. 
35 MENVEO [package insert].  Sovicille (Italy):Novartis Vaccines and Diagnostics S.r.1.  
36 Cohn AC, MacNeil JR, Clark TA, Ortega -Sanchez IR, Briere EZ, Meissner HC, et al. 
Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. Mar 22, 2013;62(RR- 2):1-28. 
37 Bonhoeffer J, Menkes J, Gold M, deSouza- Brito G, Fisher M, Halsey N, et al. Generalized 
convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine. 2004;22(5-6):557- 62. 
38 Bonhoeffer J, Menkes J, Gold MS, et al. Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine. 2004;22:557-62.  
39 Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long- term 
management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics. 2004;114(6):1708- 33. 
40 Centers for Disease Control and Prevention. Kawasaki Syndrome Case Report 2003. Available online: http://www.cdc.gov/kawasaki/pdf/ks_case_report- fillable.pdf. Accessed 
07 July 2016. 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 80 of 83
Sanofi Pasteur MET35 
395 – MenACYW Conjugate  Vaccine 
Confidential/Proprietary Information  
Page 81 of 82 41 Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain -Barré syndrome and Fisher syndrome: case 
definitions and guidelines for collection, analysis, and presentation of immunization safety 
data. Vaccine. 2011;29(3):599-612. 
42 Wise RP, Bonhoeffer J, Beeler J, et al. Thrombocytopenia: case definition and guidelines 
for collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25(31):5717-24.  
43 Chu YW, Korb J, Sakamoto M. Idiopathic thrombocytopenic purpura. Pediatr Rev. 
2000;21(3):95-104. 
44 Newcombe RG. Interval estimation for the difference between ind ependent proportions: 
comparison of eleven methods. Stat Med. 1998;17:873-90. 
 
 
Sanofi Pasteur 
 
Confidential/Proprietary Information 
              
MET35
395 – MenACYW Conjugate Vaccine
Protocol Version 3.0
Page 81 of 83